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ABSTRACT 
 
Lipoid proteinosis (LP) (OMIM 247100) is a rare autosomal recessive disorder that is 
caused by mutations within the extracellular matrix protein 1 gene (ECM1). The ECM1 
gene has been shown to play a role in angiogenesis and connective tissue matrix 
generation, especially in skin and bone. The role of ECM1 in normal skin development 
and maintenance is further highlighted by its role in LP and in lichen sclerosis where 
autoantibodies are raised against ECM1. 
 
LP usually presents in the first year of life with a faint or hoarse cry and is due to a 
hyaline-like material deposited in the mucous membranes of the vocal cords. Gradually 
(over years) there is diffuse skin infiltration and general skin thickening with a yellow, 
waxy appearance. There is excessive scarring with scars often appearing at sites of minor 
injury or stress. In many cases, the eyelids show typical beaded papules. In some cases, 
calcification of certain aspects of the temporal lobes have been observed, and may or may 
not be associated with variable neurological, psychiatric and neuropsychological 
sequelae. Although the prevalence of LP in South Africa is unknown, the 
disproportionately high number of case reports originating from South Africa indicates 
that LP is unusually common in certain South African populations, most notably the 
Coloured population of Namaqualand and the Afrikaans-speaking White population. This 
may be due to a possible LP founder effect that occurred early during the European 
colonisation of South Africa.  
 
The founder effect was investigated in the South African LP patients by conducting 
ECM1 mutation and linked marker analysis. The data supported a LP founder effect as 
the Q276X mutation in exon seven of ECM1 was present in the homozygous state in all 
LP patients investigated. In addition, the Q276X mutation was associated with a single 
founder haplotype of 19-12-23-22 (ND1-D1S2343-D1S305-D1S2624). These markers 
were in significant linkage disequilibrium with each other and with the Q276X mutation. 
 
 VI 
As variation within ECM1 may alter properties of skin such as healing and scar 
formation, ECM1 exons two through five and the first part of exon six were investigated 
for nucleotide variation using denaturing high performance liquid chromatography 
(dHPLC) and direct DNA sequencing in three different South African populations. Eight 
nucleotide variants were identified, of which six were cytosine to thymine transitions. 
Seven of the eight variants identified were either intronic or synonymous, with one 
variant being a missense variant, changing a methionine residue to a threonine residue 
(T130M). 
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CHAPTER 1 INTRODUCTION  
 
Lipoid proteinosis (LP) (OMIM 247100), is a rare autosomal recessive disorder caused 
by mutations within the extracellular matrix protein 1 gene (ECM1).1 LP is also 
commonly known as hyalinosis cutis et mucosae, lipoproteinosis or lipoid proteinosis of 
Urbach and Wiethe. LP was first described by Urbach and Wiethe in 1929.2  
 
The gene mutated in LP has been shown by Hamada et al.1 to be the ECM1 gene. 
Currently, 24 LP mutations are known,3 (I. Chan, personal communication) most of 
which have been found in the homozygous state in LP patients. Very few compound 
heterozygotes have been detected. The mutation responsible for LP in South Africa has 
been identified as the Q276X mutation in exon seven of the ECM1 gene. This mutation 
has not been described in any other population. 
 
While the genetic cause of LP is now known, the exact pathogenesis of LP is not well 
understood. The clinical manifestations have however been well documented, but show a 
great deal of variation.3,4 The most common clinical features of LP are a hoarse voice, 
excessive scarring of the skin, a widespread warty hyperkeratosis, beaded eyelid papules 
(moniliform blepharosis), a thickened sub-lingual frenulum and extensive scarring of the 
skin3,5-8. These symptoms may be partially explained by the deposition of a hyaline-like 
material under the skin or within the relevant tissue. An additional observation is that 
some LP patients exhibit psychological or neurological problems. This may be correlated 
with “bean-shaped” calcifications in the region of the anteromesial temporal lobes.9  
 
Although rare worldwide, the apparently high prevalence of LP in South Africa is 
mirrored by the largest number of LP case reports originating from South Africa. The 
majority of these LP case reports are from the Namaqualand region of South Africa. All 
confirmed South African LP patients have White ancestors, making it highly probable 
that European colonists introduced LP into South Africa. This founder effect has been 
substantiated by extensive genealogical studies on the South African LP patients in the 
late 1960s and early 1970s by authors such as Heyl and Botha.10-13  
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1.1 The Clinical Diagnosis of LP 
The clinical symptoms of LP vary substantially, not just between population groups, but 
also within population groups. This makes a definitive diagnosis very difficult to 
perform. To complicate matters, LP is rare, with multiple LP cases in a single population 
or between populations occurring rarely. This makes comparative clinical studies very 
difficult to conduct. When a large group of patients is identified, it is a reasonable 
expectation that there will be significant age differences between the patients. This 
complicates comparative clinical LP studies, as the clinical symptoms of LP are 
presumed to progress with age,4 with the symptoms becoming more detectable and 
pronounced with time. However there is a plethora of case reports on LP patients in the 
literature, and from these sources, it is possible to extract the most universal clinical 
symptoms of LP, some of which are presented in Figure 1-1. 
 
A clinical diagnosis should be suspected when a patient presents with a hoarse voice that 
has been present since birth or early childhood, generally thickened and scarred skin, 
beaded eyelid papules and a thickened sub-lingual frenulum. Other confirmatory 
symptoms are infiltrated warty skin papules especially on the elbows and extensor 
aspects of the forearms and oval bilateral, symmetrical calcifications of the anteriomedial 
aspect of the temporal lobes (Figure 1-1). 
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Figure 1-1: Common LP manifestations 
A: Beaded eyelid papules. B: Thickened vocal cords causing the typical hoarse voice. C: Warty, infiltrated 
skin papules on the elbow and scarring of the arm. D: Warty hyperkeratosis of the palm. Images A to D are 
taken from Hamada et al., 2002.1 E: Thickened sub-lingual frenulum leading to reduced tongue movement 
and inability to protrude the tongue normally from the mouth. Note the excessive scarring of the face and 
thickened lips. Courtesy of Prof. T. Jenkins. F: Oval bilateral, symmetrical calcifications of the 
anteriomedial aspect of the temporal lobes. Taken from Emsley and Paster, 1985.14 
 
1.1.1 Skin Manifestations of LP 
Next to the hoarse voice, the most noticeable clinical manifestation of LP is excessive 
scarring and infiltration of the skin, which usually develops within the first years of life.8 
There are recurrent pustules or bullae on the face and on the exposed surfaces of the arms 
and legs, which can result in white variloform or acneiform scars. As the patient ages, 
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skin lesions can include yellow, waxy papules, nodules and verrucoid plaques that are 
commonly on the elbows and knees.15,16 Eventually the skin takes on a characteristic 
yellowish colour, has a waxy texture and is thickened (hyperkeratosis), especially at areas 
where the skin is stretched constantly, for example the elbows, hands and knees.8,17 The 
skin of the hands and elbows may show infiltrated, warty papules (Figure 1-1 D, Figure 
1-2 D), which may be exacerbated by excessive manual labour or prolonged exposure to 
detergents. Scarring of the skin occurs typically after trauma, but there have been cases 
reported where the scarring has occurred spontaneously. Scarring usually begins in 
childhood and is particularly noticeable on the face.17 Interestingly, it has been reported 
that scarring may not occur after surgery, such as tracheostomies, or after vaccination. 
However, scarring will often occur at sites of minor stresses such as grazes or the 
stretching of the skin.4 
 
 
 
Figure 1-2: Common LP skin manifestations 
A: Excessive scarring of the face with warty, infiltrated papules in the patients ears. B: Warty, infiltrated 
papules of the elbows. C: Typical pockmark scarring of the calf. D: Hyperkeratosis of the hands. Images 
are of South African LP patients only. 
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1.1.2 Psychological and Neurological Manifestations of LP 
It has been reported that certain LP patients may show some form of psychological or 
neurological problems, with the most common symptom being minor nervous 
disturbances and/or epilepsy. It has also been noted that some LP patients have oval or 
bean-shaped calcifications in the anteriomedial aspect of their temporal lobes (Figure 1-1 
F).14 While this may be the reason behind the psychological problems seen in LP patients, 
the correlation between the calcifications and the psychological problems has not been 
thoroughly investigated.3  
 
1.1.3 Biochemical and Histological Manifestations of LP 
The main manifestations of LP are related to the deposition of an amorphous hyaline-like 
material in connective tissues. This hyaline-like material displays a periodic acid–Schiff 
(PAS) positive reaction, is resistant to enzyme digestion and is eosinophillic. The hyaline 
material is often deposited around the walls of small and medium sized blood vessels in 
the papillary dermis, which then shows a typical “onion-skin” proliferation of the 
adventitia. Under electron microscopy, the deposit is comprised of small granules and 
short filaments that are electron lucent.6 
 
Harper et al.18 have shown that LP skin has significantly less collagen per unit dry weight 
than normal skin. The total collagen content of dried LP skin was 36%, compared to 
normal skin having 52-53%. However, a generalized increase in basement membrane 
collagens was found in LP patients, with elevated levels of collagen type III with respect 
to collagen type I. Immunohistochemistry has shown that there is a patchy and diffuse 
distribution of collagen type III and a relative increase in collagen types IV and V. This is 
associated with an “onion skin” appearance around endothelial basement thickening. 
Estimation of collagen cross-links showed an abnormal pattern with a preponderance of 
the keto-imine form not normally associated with skin. Harper et al.18 puts forward that 
these results suggest that LP involves a primary perturbation of collagen metabolism.  
Also, no abnormal collagens were purified from LP skin after pepsin degradation.  
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Bauer et al.19 reported numerous vacuoles in LP fibroblasts that are not present in normal 
fibroblasts. When LP fibroblasts were examined under electron microscopy, the 
fibroblasts displayed striking similarities to known lysosomal storage disorders and this 
lead Bauer et al.19 to postulate that the material in LP patients represents a complex 
glycoprotein present in increased amounts and is likely to be as a result of a single or 
multiple enzyme defects. 
 
It is important to note here that a limited number of cases (usually not more than three 
patients) were investigated in each histological and/or biochemical study that was carried 
out on LP skin and hence it is not advisable to extrapolate these results to all cases and to 
generalise about a situation in LP.  
 
1.2 LP in South Africa 
The relatively common occurrence of LP in South Africa has led many researchers10-13 to 
conclude that there has been a founder effect that occurred early on in South Africa’s 
history.20 The populations affected by LP in South Africa are the Afrikaans-speaking 
Coloured population of Namaqualand and the Afrikaans-speaking White population.  
 
As LP has not yet been documented in the Black or Khoisan populations of South Africa, 
it is reasonable to conclude that LP is not common in the South African Black population 
or the Khoisan population of Namaqualand. Therefore the White population is the most 
likely population to have introduced the LP mutation into the South African population. 
This is supported by genealogical studies10-13,20 that have traced the pedigrees of many of 
the White and Coloured families with LP back to the following ancestors of European 
descent: Gerrit or Elsje Cloete, Jan van den Heever and Piet Engelbrecht. The 
predominance of the surname Cloete and the fact that many LP family pedigrees 
investigated by Heyl11,12 and Gordon et al.13,20 have shown at least one common ancestor 
in either Gerrit or Elsje Cloete, allows one to conclude that this Cloete sib pair is likely to 
be responsible for introducing the LP causing mutation into the South African population. 
Gerrit and Elsje Cloete’s ancestry traces back to their great-grandfather, Jacob Cloete 
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from Cologne, Germany. Jacob Cloete’s son, who was also named Jacob Cloete, was one 
of the initial settlers of the Cape colony with Jan van Riebeck in 1652, and is thought to 
be the progenitor of the large number of Cloete families in South Africa today. 
 
In a separate study on the Rhenish Mission in South Africa, Strassberger21 mentions a 
Jasper Cloete who arrived in the settlement at Komaggas in Namaqualand in 1790 when 
he was rejected and expelled from his family farm in the Kammies mountains. His three 
White half-brothers rejected him, as he was a “half-caste” or Coloured. It is not clear as 
to how or if Jasper is related to Jacob Cloete. However Jasper may be responsible for 
introducing the LP mutation into the Coloured population of Namaqualand, while his 
half-brothers, together with the other descendants of Elsje and Gerrit Cloete, are likely to 
be the progenitors of the individuals with LP in the White population of South Africa. 
 
This presents strong evidence that the mutation responsible for causing LP was 
introduced into South Africa with the very first White settlers and that the original 
founder may have entered South Africa as early as 1652. 
 
1.3 Founder Disorders in South Africa 
The first White settlers arrived in South Africa in 1652 and at this time the White 
population was relatively small. This population was likely to have been a representative 
sample that did not differ significantly from the parent European population. However, 
due to the small population size of the original White settlers, it is probable that the 
frequency of many genotypes would have been distorted, raising (or lowering) the 
frequency of some rare genotypes and lowering the frequency of other common 
genotypes. This raising of rare genotype frequencies due to a small subsection of a 
population migrating from the parent population and establishing a new population with 
the same genotypes but at differing frequencies, is termed a founder effect.  
 
The founder effect can be more or less 'fixed' if the new population expands rapidly. If 
the population size remains moderate, consanguinity is likely to be relatively common 
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and the frequency of recessively inherited conditions will be increased. The above 
scenario is likely to have occurred in South Africa, as there are many South African 
founder effect examples. Genetic disorders such as variegate porphyria,22,23 familial 
hypercholesterolemia,24 pseudoxanthoma elasticum25,26 and Fanconi anemia27 are 
remarkably common in South Africa, and the relatively high frequency of each disorder 
is thought to be primarily due to a founder effect. The possible addition of LP to this list 
is therefore not surprising, as Gorden13,20 and Heyl10,11 have shown that all LP patients 
they studied could be traced to a sib pair who arrived in South Africa shortly after 1652. 
However, further molecular genetic work will be needed to substantiate Gordon and 
Heyl’s findings. 
 
1.4 Identification of ECM1 as the “LP” gene 
Early in 2002 Hamada et al.1 announced that they had identified the gene that was 
mutated in LP patients. The gene mutated was the ECM1 gene, and it was noted that all 
the populations with LP that were studied had a mutation unique to each population. 
Compound heterozygotes were very rare.1,3  
 
In order to identify the LP gene, Hamada et al.1 used a standard genome wide linkage 
analysis to identify a 2.3 centiMorgan interval on chromosome 1q21 that showed strong 
linkage at marker D1S498, with a maximum two point LOD score of 21.85 (θ = 0). The 
critical interval was then focused on a ~6.5Mb section of 1q21 between markers 
D1S2344 and D1S2343 using observed recombinations within the haplotypes. This 
interval contained 68 known genes or in silico predicted genes. A positional candidate 
gene approach was then used to identify which of these 68 genes was the LP gene. To 
narrow down the number of positional candidates, the mRNA from LP fibroblasts was 
examined for mRNA levels of each candidate gene. If there is a homozygous nonsense 
mutation within one of the candidate genes, the resultant mRNA from that gene is 
thought to have a shortened half-life due to a process known as nonsense mediated 
mRNA decay. This would result in low levels of the candidate gene’s mRNA present in 
an affected tissue.28 This is contrasted with mRNA levels of the same gene in an 
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unaffected individual’s tissue.29 Therefore, as LP is primarily a skin disorder and as there 
have been reports that fibroblasts are abnormal in LP patients,19 mRNA derived from LP 
fibroblasts were investigated by Hamada et al. for nonsense mediated mRNA decay of 
the 68 positional candidate genes. This was accomplished using reverse transcription 
PCR (RT-PCR). The results were compared to results similarly obtained from normal 
fibroblast mRNA. ECM1 mRNA was found to be decreased in LP fibroblast mRNA 
relative to ECM1 mRNA from normal fibroblasts. ECM1 was therefore a good candidate 
gene and was investigated further. 
 
Direct sequencing of ECM1 from genomic DNA from LP individuals allowed Hamada et 
al.1 to identify three nonsense mutations: a single nucleotide insertion, a single nucleotide 
deletion and a large (1.1kb) deletion. Each mutation was found in a separate population 
and each was present in the homozygous state in affected individuals, in the heterozygous 
state in obligate carriers and none of these mutations were found in 80 ethnically diverse 
normal controls. Further studies have now identified that there are at least 24 mutations 
that are pathogenic for LP.3 (I. Chan personal communication) 
 
1.5 The ECM1 gene 
The ECM1 gene is located on chromosome 1q21.2, is comprised of 11 exons and spans 
5454 nucleotides. It is located close to, but not within, the epidermal differentiation 
complex on chromosome 1.30 ECM1 has two alternatively spliced exons, exon 5a and 
exon 7 (Figure 1-3). This results in three ECM1 isoforms, namely ECM1a, which 
contains all exons except for exon 5a, ECM1b, which contains all exons except for exons 
5a and 7, and ECM1c, which contains all 11 exons.  
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Figure 1-3: Genomic positioning of ECM1 
The image on the left shows chromosome 1 with the banding patterns obtained with standard giemsa 
staining. The image in the middle shows an enlarged picture of the 1q12 to 1q23 area of chromosome 1 and 
indicates where ECM1 is found in band 1q21.2. The middle image shows the position of the four 
microsatellite markers used in this study. All data for the middle image were compiled from the UCSC 
genome browser July 2003 freeze. The rightmost image is an enlarged image of the ECM1 gene. The 
numbers refer to the different exons of ECM1; the broken lines indicate areas not drawn to scale. The 
shaded exons indicate exons that are alternately spliced (exons 5a and 7) while the blacked out parts of 
exons 1 and 10 indicate the 5’ and 3’ untranslated regions, respectively. 
 
ECM1a is expressed predominantly in the heart and placenta, but is also found in the 
skin, liver, ovary, kidney, lung, pancreas, testis, muscle and colon,31,32 while expression 
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of ECM1b has been described only in skin and tonsils.30,33 ECM1c expression has only 
been detected in two cancer cell lines31 and is thought to constitute ~15% of total ECM1 
mRNA expression in those cells. In other studies, ECM1 has been implicated in 
promoting angiogenesis in the chorioallantoic membrane of the chicken egg and to 
promote endothelial proliferation in the mouse,34 while ECM1a has been shown to 
regulate bone alkaline phosphatase activity.35 Very little is known about the expression 
pattern of ECM1b, except that it is expressed after cultured keratinocytes have almost 
completely differentiated (ECM1a is expressed throughout all three stages of 
differentiation).35 The expression profile of ECM1c is unknown. Additionally, increased 
ECM1 expression elucidated by microarray experiments has been reported in cartilage 
formation,36 dendritic cell differentiation and maturation,37 as well as in grade I, II and IV 
glioblastoma multiformes.38 Apart from dendritic cell differentiation and maturation, 
these processes involve extracellular matrix generation and vascularisation of the 
respective matrix/tissue, which further accentuates ECM1’s role in angiogenesis and 
metabolism of extracellular matrices in general. 
 
The ECM1 protein is made up of five domains, of which the first domain is a cysteine 
free putative signal peptide at the N terminus consisting of 19 amino acids. The second 
domain is also a cysteine free domain (from amino acid position 20 to 150), while the 
third and fourth domains are two tandemly repeated domains (positions 151 to 279 and 
280 to 405, respectively) each with a cysteine repeat pattern of CC-(X7-10)-C.30 This 
pattern is strikingly conserved between the mouse and human, with the number of 
cysteines being almost identical (28 residues in the human protein compared to 29 
residues in the mouse protein. The extra cysteine residue in the mouse is found in the 
signal peptide). The last domain is a C-terminal region that also contains cysteines 
arranged in the CC-(X7-10)-C pattern. The CC-(X7-10)-C pattern is predicted to form 
double loop domains, which are involved in ligand binding in the serum albumins.30(Op. 
Cit) 
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Figure 1-4: Schematic representation of the three ECM1 protein isoforms showing their respective 
domains in relation to ECM1 exons one to ten 
 
The conservation of the cysteine pattern between mouse and humans implies that the 
ECM1 protein is under severe structural constraints for these cysteine double-loop 
domains and hence these structures are likely to be important for ECM1 function. 
ECM1b has exon seven alternatively spliced out and this removes the second tandemly 
repeated domain, leaving only two CC-(X7-10)-C patterns. This may alter the ligand 
binding properties of ECM1b. It is interesting to note that the majority of LP causing 
mutations are within the seventh exon or occur before it. This implies that the ECM1a 
isoform is the isoform that plays the major biological role in humans. With regard to the 
South African LP mutation (Q276X), the ECM1b isoform would have the mutation 
spliced out and could theoretically function normally. However this does not “rescue” the 
LP patient from the pathological affect of the Q276X mutation, which therefore 
highlights the biological importance of ECM1a. The addition of exon 5a into the ECM1c 
1        2   3     4   5      5a        6             7             8       9        10 
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protein is predicted to increase the length of the N terminal domain by 12 amino acids, 
but not to affect the cysteine pattern. The function of ECM1c is therefore arguably 
identical to that of ECM1a. 
 
With regards to known mutations that are pathogenic for LP, all 24 mutations result in the 
perturbation of ECM1a and ECM1c expression, while ECM1b expression is only affected 
by the mutations outside exon seven (15/24 of LP mutations lie outside ECM1 exon 
seven). This again highlights the biological importance of ECM1a and possibly ECM1c, 
as ECM1b cannot rescue the LP phenotype when a mutation occurs within ECM1 exon 
seven, which could be alternatively spliced out before translation. 
 
Recently, Mongiat et al.31 published a paper in which he reports that ECM1 interacts with 
domain V of perlecan in a specific manner. Perlecan itself is a modular heparan sulfate 
proteoglycan that is an intrinsic constituent of basement membranes. It has been 
implicated in roles of vasculogenesis, thrombosis, tumorigenesis, and angiogenesis and 
acting in concert with other extracellular matrix molecules, it maintains structural 
integrity of vessel walls.31 Interestingly, ECM1 and perlecan are co-expressed in similar 
regions of the dermis, and notably within the collagen-rich regions of the upper dermis. 
This co-expression pattern is interesting as the basement membranes immediately around 
vessels in the dermis in LP patients show a thickening or re-duplication. Therefore the 
lack of ECM1 interacting with perlecan in LP individuals may be a direct or indirect 
cause. 
 
1.6 Implications of ECM1 as the LP gene 
Once the ECM1 gene had been identified as the “LP” gene, various interesting points 
became evident. Hamada et al.1 noted that there was strong linkage to marker D1S498, 
with a two point LOD score of 21.85 (θ = 0) with six LP families. The LOD score 
dropped to 3.45 (which is a borderline value for LOD scores, a LOD score of 3.00 and 
above is considered significant) when five of the families were removed from the 
analysis. These five families totalled 28 individuals, of which 22 were actually a cohort 
 14 
of South African LP individuals who were assumed to be related because of the proposed 
founder effect put forward by Heyl and Gordon.10-13,20 
 
The study by Hamada et al.1 also noted that mutations within the alternatively spliced 
exon seven of ECM1 seemed to result in a milder phenotype than phenotypes that arose 
from mutations outside exon seven. Subsequent studies by Hamada et al.3 have noted that 
there is considerable phenotypic variation of LP between and within families. Also, in a 
recent genotype-phenotype correlation study on Namaqualand LP individuals, it was 
noted that while the LP individuals studied were all homozygous for the Q276X mutation 
(i.e. they were genotypically identical), there was considerable phenotypic variation (J. 
McGrath, personal communication). The lack of genotype-phenotype correlation may be 
partially explained by the observation made by Hamada et al.3 who noted that partial 
reinstatement of ECM1 expression was made possible by restoration of the open reading 
frame of ECM1 mRNA by the splicing out of exons three and four. The patient was 
homozygous for the mutation 243 del G (nt 1732 del G) in exon four and the clinical 
manifestation of LP in this individual was noted to be mild. This restoration of the 
reading frame was termed aberrant by Hamada et al. as many other alternatively spliced 
ECM1 transcripts were seen that did not reinstate the open reading frame. Therefore, the 
lack of genotype-phenotype correlation seen in the Namaqualand LP patients and LP 
patients worldwide may in part be explained by partial rescue of ECM1 expression by the 
in frame splicing out of the mutated exon. Therefore variation that alters ECM1 splicing 
may be able to reduce the symptoms of LP and hence explain the lack of genotype-
phenotype correlation. Additionally, variation in other genetic factors whose protein 
products play a role in the same physiological pathways as ECM1 cannot be excluded as 
a source of the discordance between genotype and phenotype in LP individuals.  
 
ECM1 is involved in many important physiological processes such as angiogenesis, 
which is an important factor in tumorigenesis and connective tissue matrix formation 
such as skin and bone formation. Variation that alters the activity or amounts of ECM1 
produced will be of great scientific and possibly medical interest. Association studies 
could be done to examine the role of ECM1 in scar formation, in solid tumour 
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vascularisation and in other common skin and bone abnormalities, such as acne and 
osteoporosis. 
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AIMS 
 
The objective of this study was to investigate and provide scientific support for the LP 
founder effect within South Africa and to identify polymorphic variants within the ECM1 
gene in representative South African populations. To accomplish this, the following aims 
were pursued: 
 
1) To identify the gene mutations responsible for LP in South African LP patients 
from different populations. 
2) To estimate the carrier frequency of the Q276X mutation in the Namaqualand 
Coloured population, the Gauteng White population and the South African White 
population. 
3) To identify a founder haplotype(s). 
4) To determine the extent of linkage disequilibrium around the Q276X mutation in 
LP patients. 
5) To screen ECM1 exons two through five and the first part of exon six for variants. 
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CHAPTER 2 SUBJECTS AND METHODS 
 
2.1 SUBJECTS 
All samples from Namaqualand are from individuals referred to as Coloureds, who are all 
Afrikaans-speakers. The Coloured individuals are descendants of the admixture between 
the early Caucasoid immigrants of South African and the indigenous Khoisan peoples of 
Namaqualand.39 The term Coloured is loosely defined and the Coloured population in 
Namaqualand is genetically distinct from the Coloured populations found in Gauteng and 
other parts of South Africa.  
 
Blood samples were collected by registered doctors and nurses, after informed consent. 
Samples were collected from 29 Coloured LP patients, from 28 of their immediate family 
members and 100 randomly selected control individuals from the Coloured population in 
Namaqualand. A group of seven White LP patients and five of their immediate family 
members were also investigated, and blood was drawn from these individuals after 
informed consent. The White LP families reside in Gauteng, Kwa-Zulu Natal and 
Mpumalanga. The majority are Afrikaans-speakers. 
 
In addition to this, 50 random White DNA samples and 20 random Black DNA samples 
were obtained from the Human Molecular Genetics Laboratory random sample 
collection. 
 
Ethics approval for this study was obtained from the Human Research Ethics Committee 
of the University of the Witwatersrand, Johannesburg, South Africa (Protocols M01-01-
19 and M02-04-31, Appendix 5-10). 
  
 18 
2.2 METHODS 
2.2.1 DNA Extraction 
Where DNA was not readily available, whole blood was collected in ACD tubes and 
genomic DNA was extracted using a protocol adapted from Miller et al.40 (Appendix 
5.1). 
 
2.2.2 Polymerase chain reaction (PCR), gel electrophoresis and BfaI restriction 
endonuclease digestion for Q276X screening 
2.2.2.1 PCR 
To screen for the mutation Q276X, PCR was employed, as it is a simple and reliable 
technique that is capable of exponentially amplifying small sections of genomic and other 
DNA. PCR is a simple 5-step technique that is accomplished by denaturing the template 
DNA, annealing the primers to the target sequences and then the elongation of the 
primers using a thermal stable DNA polymerase from the bacterium Thermus aquaticus. 
It is the repetition of these three steps that results in the exponential amplification of the 
target sequence.  
A typical PCR reaction consists of the following 5 steps: 
Step 1: Denaturing step at 94oC for ~5 minutes. 
This step denatures all double stranded (ds)DNA in the reaction to single stranded 
(ss)DNA, thereby allowing the primers access to the target sequence. 
The next three steps (steps 2-4) are usually repeated 25 to 30 times.  
Step 2: Denaturing step at 94oC for ~30 seconds.  
 To denature dsDNA to ssDNA. 
Step 3: Annealing step at ~55oC (usually between 45oC and 65oC) for ~30 seconds. 
The annealing temperature is primer specific, and each primer set will have a 
unique annealing temperature. 
Step 4: Elongation step at 72oC for ~30 seconds. 
This step is carried out at the Thermus aquaticus DNA polymerases (Taq) 
optimum temperature. This enzyme polymerises complimentary dNTPs to the 3’ 
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hydroxyl group of the primer, and thereby extends the primer in a 5’ to 3’ 
direction. 
Step 5: Elongation step at 72oC for ~10 minutes. 
 This is a final primer extension step. 
 
The primers are central to the PCR reaction. They must be designed to flank the region of 
interest. Therefore two primers are needed for a complete PCR reaction: a forward and a 
reverse primer. In each cycle (steps 2-4), the two primers anneal to their complimentary 
ssDNA sequences, after which the Taq polymerase covalently bonds complimentary 
dNTPs (to the target strand) to the 3’ hydroxyl group of the primers.41-43A generic PCR 
protocol is shown in Table 2-1. 
 
Table 2-1: Generic PCR protocol 
Thermal Cycling 
Conditions 
Description Stock Concentration Volume 
Forward primer 10 pM 1µl 
Reverse primer 10 pM 1µl 
PCR Buffer 10x 2.5µl  
dNTPs 1.25 mM 2.5µl  
ddH2O N/A 16.8µl 
Taq DNA 
Polymerase  5 Units/µl 0.2µl  
DNA ≥ 100ng/µl 1µl  
 
 
94oC → 5 minutes 
94oC → 30 seconds     
XoC  → 30 seconds        30x         
72oC → 30 seconds 
72oC → 10 minutes 
24oC → hold 
TOTAL N/A  25µl  
XoC is the optimal annealing temperature for the chosen primer pair. Increasing or decreasing the number 
of cycles can increase or decrease the yield of amplified DNA, respectively. 
 
Exon seven of the ECM1 gene was PCR amplified with exon seven specific primers 
situated in the introns flanking the exon (ECM1 Ex 7F 5’ TTA TCT GCC TGC CCA 
GTG TC 3’, ECM1 Ex 7R 5’ ACA TGG ATG GAT GGA CTG GC 3’) according to the 
protocol in Table 2-1 with an annealing temperature of 58.5 oC. This resulted in a PCR 
product of 548bp. Primers were designed using the computer program DNASTAR 
PrimerSelect. 
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2.2.2.2 Gel electrophoresis 
To determine if the PCR reaction was successful, a small volume of PCR product 
(usually 5µl) was electrophoresed on an agarose gel. The PCR product was mixed with 
Ficoll dye (this helps the sample to sink into the well, and was used as an indicator of 
how far the smaller DNA fragments have run in the gel), was loaded into a well, and a 
current was applied to the gel (the gel was placed in a tank containing 1x TBE buffer, 
which conducts the current). The current varies with the conductivity of the 1xTBE 
buffer, but the voltage was set at 120V. The electrodes were spaced 30cm apart, with the 
gel placed between them. As DNA is negatively charged, the samples were placed in the 
area of the gel closest to the negative electrode, so that the sample will pass through the 
gel as it moves towards the positive electrode.43 
 
Ethidium bromide was added to the gel as it was prepared. When the PCR product was in 
the gel, the ethidium bromide would intercalate into the dsDNA of the PCR product, and 
when exposed to ultra-violet light (260nm), it would fluoresce. This was used to detect 
the presence of DNA in the gel and the presence was recorded by photographing the 
image of the gel illuminated by ultra-violet light.  
 
In order to confirm that the correct PCR product had been amplified, a size standard was 
loaded onto each gel. The size standard contains DNA fragments of known sizes, and the 
size of the PCR fragment was estimated by comparing it to the size standard. The size 
standards used in this study were the 1kb and the 1kb plus ladders (Figure 2-1 lane 1 and 
6, respectively). 
 
To confirm that the PCR of ECM1 exon 7 was successful, 5µl of the PCR product was 
electrophoresed on a 2% agarose gel for approximately 30 minutes, and sized using the 
1kb or 1kb plus ladders. If a single band was present at the expected size range of 548bp 
(Figure 2-1, lane2), the remaining PCR product (20µl) was digested with the restriction 
endonuclease BfaI. 
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Figure 2-1: Schematic representation of the expected ECM1 Ex 7 restriction digestion pattern run on 
a 2% agarose gel. All sizes are in base pairs. 
Lane 1: A section of the 1kb ladder. Lane 2: ECM1 Ex7 uncut PCR product. Lane 3: Homozygous WT BfaI 
digestion pattern. Lane 4: Heterozygous WT/Q276X BfaI digestion pattern. Lane 5: Homozygous Q276X 
BfaI digestion pattern. Lane 6: A section of 1kb plus ladder. All numbers are in base pairs. WT: wild type 
(non-Q276X) allele. 
 
2.2.2.3 BfaI restriction endonuclease digestion 
Type II restriction endonucleases are enzymes produced by micro-organisms that 
recognize specific DNA sequences, bind to these sequences and cut the DNA strands at 
that site. Restriction endonucleases are useful tools in molecular biology, as they will 
only cut at their specific recognition site. If the recognition site is altered in any way, 
such that just one base of the recognition site is changed, the restriction endonuclease will 
not recognize or cut that altered recognition site. 
 
The restriction endonuclease used to detect the Q276X mutation was BfaI, which 
recognizes and cuts the sequence 5’CTAG3’. The mutation Q276X is a C → T transition, 
changing a 5’CCAG3’ sequence to a 5’CTAG3’ sequence, thereby creating a new BfaI 
recognition sequence. In PCR products amplified from normal individuals without the 
83 83 
120 
345 345 
120 
83 
465 465 
100 
200 
300 
400 
500 
650 
850 
1000 
75 
154 
134 
201 
220 
296 
344 
396 
506 
517 
1018 
1  2  3  4  5  6 
548 
 22 
mutation Q276X, there is one BfaI recognition site and when digested with BfaI, results 
in two fragments sized 83bp and 465bp (Figure 2-2A). In PCR products amplified from 
LP individuals (who are homozygous for the mutation Q276X), the Q276X mutation 
introduces a second BfaI restriction site (Figure 2-2B) and therefore digestion with BfaI 
will result in three fragments sized 83bp, 365bp and 120bp. The initial BfaI restriction 
site is present in PCR products amplified from all individuals, and therefore acts as a 
positive internal control for digestion with BfaI. 
 
 
 
Figure 2-2: BfaI restriction map of the 548bp PCR fragment 
BfaI recognition sites are shown with red arrows. The mutation Q276X is shown. Part A indicates how BfaI 
will cut the 548bp fragment when the mutation Q276X is absent, while part B indicates how BfaI will cut 
the fragment if the mutation Q276X is present.  
 
If PCR of a sample was successful, the sample would then be dialyzed on a 0.025µm 
filter paper suspended in a petridish of ddH2O for two hours to remove any salts that 
could inhibit the digestion of the PCR product. Once purified, the PCR product would 
then be digested with BfaI according to the protocol in Table 2-2. 
 
Table 2-2: Conditions of ECM1 Ex 7 Restriction Digestion with BfaI 
Thermal Conditions Description Stock Concentration Volume 
NEBuffer 4 10x 3µl 
ddH20 N/A 3µl 
BSA 10% 3µl  
BfaI 5 Units/µl 1µl 
Purified ECM1 Ex 7 PCR 
product N/A 20µl 
37oC for four days 
TOTAL N/A  30µl  
 
Q276X 
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No STAR activity (where a restriction enzyme cuts a DNA strand at a site that does not 
correspond to its recognition sequence44,45) has been noted for the BfaI enzyme, but it 
was noted that BfaI commonly only partially digests PCR products (P. Walsh, personal 
communication;http://www.neb.com/neb/tech/tech_resource/restriction/properties/primer
_extension.html).46 It was therefore necessary to incubate the samples for four days 
instead of the usual three hours or overnight. The resultant products were electrophoresed 
on a 2% agarose gel submerged in 1xTBE buffer at 120V with the electrodes spaced 
30cm apart. The gel was electrophoresed for at least 30 minutes and then viewed by 
trans-illumination of ultraviolet light (260nm) on the Gel Documentation system. The 
image was then captured electronically. 
 
If the sample digested with BfaI was a non-Q276X homozygote, the expected fragment 
pattern after gel electrophoresis is shown in Figure 2-1 lane 3, while if the sample 
digested was a Q276X homozygote, the expected fragment pattern is shown in Figure 2-1 
lane 5. If the sample digested was a heterozygote for the mutation Q276X, the expected 
fragment pattern is shown in Figure 2-1 lane 4. 
 
2.2.3 Dinucleotide microsatellite genotyping 
To determine the extent of linkage disequilibrium (LD) around the ECM1 gene in the 
South African LP population, six dinucleotide microsatellite markers (D1S2863, 
D1S2696, D1S2636, D1S2343, D1S305 and D1S2624) around the ECM1 gene were 
initially typed in all affected individuals, their immediate family-members when available 
and in 80 random ethnically and geographically matched controls (50 Coloured and 30 
White individuals). The markers were chosen to span an estimated area of 10.5Mb of 
chromosome one, with ECM1 near the centre of this area. However, three of these 
markers had to be discarded at a later stage (D1S2863, D1S2696 and D1S2636) as they 
were found to be too far away (> 50 megabases (Mb), or across the centromere) from 
ECM1 and hence would not be informative. This was due to the UCSC genome 
bioinformatics browser (http://genome.ucsc.edu) reassembling the available sequence of 
chromosome one, as fresh sequence was made available, with the newer version or 
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“freeze” moving the markers further away than was originally anticipated. To facilitate 
effective coverage of the genomic region surrounding ECM1, three of the initial markers: 
D1S2343, D1S305 and D1S2624 that were telomeric to ECM1 were used while a single 
new dinucleotide microsatellite marker was identified centromeric to ECM1. This new 
marker was named Novel Dinucleotide 1 (ND1). Figure 2-3 illustrates the position of the 
dinucleotide markers relative to ECM1. 
 
ND1 was identified by downloading approximately 5Mb of sequence centromeric to 
ECM1 from the UCSC website and inputting the sequence into the computer program 
“Tandem Repeat Finder” (TRF).47 TRF can identify all repeating sequences within a 
specific input sequence, and the user can then pick any of these to suit their needs. For 
this study, a dinucleotide microsatellite 3.82Mb from ECM1 was chosen. This was done 
as preliminary results from the markers telomeric to ECM1 showed strong LD at a 
distance of 3.80Mb from the Q276X mutation. This marker became known as ND1 and 
primers were then designed to flank the repeat sequence of ND1 using the software 
program DNASTAR PrimerSelect. 
 
All of the markers were confirmed by BLAT searches against the UCSC genome 
bioinformatics browser and information pertaining to them, with the exception of marker 
ND1, can be found at the Genome Database (GDB) (http://gdb.org), the National Center 
for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov/) and the UCSC 
genome bioinformatics browser (http://genome.ucsc.edu). 
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Figure 2-3: Schematic representation of the microsatellite markers surrounding ECM1. 
Distances estimated from the UCSC website. Mb denotes megabases. Broken lines indicate areas not drawn 
to scale. 
 
Table 2-3: Primer sequences of the four microsatellite markers used in this study 
Marker 
Name 
Primer Name Sequence 
ND1 F 5’ HEX TGT GGG GAG AAA GTG GAT AGT T 3’ ND1 ND1 R 5’ CTC ATT TGC TTG GGG TGT CT 3’ 
D1S2343 F 5’ HEX GTT TCT TGG GTG GAT CAC TTA AGC CT 3’ D1S2343 D1S2343 R 5’ CTA GCA TAT TCG TCC TGA ACT AA 3’ 
D1S305 F 5’ FAM CCA GNC TCG GTA TGT TTT TAC TA 3’ D1S305 D1S305 R 5’ CTG AAA CCT CTG TCC AAG CC 3’ 
D1S2624 F 5’ HEX CTG CGT CTC TTC CCT CCA TAC ACA 3’ D1S2624 D1S2624 R 5’ AGC GTC CTG CAC AGA GTC CAA CC 3’ 
F indicates forward primers, while R indicates reverse primers.  
 
Each marker was PCR amplified with fluorescently labelled primers (Table 2-3), for each 
individual under the conditions set out in Tables 2-1 and 2-4. 
 
Table 2-4: Microsatellite marker PCR conditions 
Marker Name Annealing Temperature Expected Product Size 
ND1 58.5 oC 211bp – 229bp (15 repeats to 24 repeats) 
D1S2343 55oC 246bp – 282bp (10 repeats to 28 repeats) 
D1S305 56oC 167bp – 195bp (18 repeats to 32 repeats) 
D1S2624 66oC 327bp – 351bp (12 repeats to 24 repeats) 
 
One microlitre of each resultant product was mixed with 2.2µl dextran-formamide dye 
and 0.3µl of GeneScan 500 Rox Size Standard. The resultant mix was then denatured 
at 98 oC for two minutes, and then immediately put on ice. Either 1.5µl or 1.7µl of 
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denatured sample mix was loaded onto a 36 or 24 lane (respectively) denaturing 4.3% 
polyacrylamide 36cm gel and electrophoresed using an ABI 377 Sequencer. The raw 
fluorescent data was captured by the ABI 377 collection software v.2.1 with filter set A 
and then analysed with the Genescan v.3.1.2 and Genotyper v.2.5 software programs. To 
avoid errors introduced by intergel variability, a homozygote and heterozygote of known 
size was added to each gel as a size control. 
 
Ideally, for each marker an individual who is homozygous at that marker should be 
sequenced, thereby allowing the number of repeats to be directly counted and associated 
with a specific allele size estimated by the Genescan v.3.1.2. This can then be used as a 
benchmark whereby all other allele sizes for that marker can directly be correlated to a 
repeat number. However, due to time constraints, this was not done, and instead a number 
of repeats was assigned to a particular allele size by estimating this from the published 
sequence at the UCSC website (http://genome.ucsc.edu). 
 
Family pedigrees were constructed for the LP families and phase of the alleles for each 
marker was determined using the pedigrees, thus producing haplotypes. Phase and hence 
haplotypes could not be deduced from the random Coloured or White individuals as there 
was no pedigree information available. Haplotypes were then estimated using the 
Arlequin v1.1 software program, which is available at http://lgb.unige.ch/arlequin/.  
 
2.2.4 Variation screening in the ECM1 gene 
2.2.4.1 PCR 
To screen the coding region of ECM1 for polymorphisms, each of ECM1’s exons were 
PCR amplified from 60 random individuals. The 5’ and 3’ untranslated regions were 
excluded, as they do not code for amino acids. Exon 5a was not included in this study as 
it was discovered to be a coding exon in humans only in the first half of 2003.30,31 
 
The primers were designed using the software program DNASTAR PrimerSelect, and 
since the amplimers were intended for denaturing high performance liquid 
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chromatography (dHPLC) analysis, the primers were designed such that they produced 
amplimers no greater than 400bp. The reason for this is discussed on pages 29 and 30. 
 
Each ECM1 exon was PCR amplified in 60 random individuals, 20 individuals from three 
distinct South African population groups, namely the Black population, the Coloured 
population, and the White population. The PCR conditions are described in Tables 2-1 
and 2-6 and use the primers described in Table 2-5. 
 
Table 2-5: Primer sequences used to identify variants within the ECM1 gene 
ECM1 Exon Primer Name Sequence 
ECM1 Ex 1 F 5’ GAGGGCGGGAGATCACACCAG 3’ ECM1 Ex 1 ECM1 Ex 1 R 5’ CAAGCCCAGACCCCCTCCTAAGT 3’ 
ECM1 Ex 2 F 5’ ACGGGGCAGGTGAATACAGAG 3’ ECM1 Ex 2 ECM1 Ex 2 R 5’ TAGAAGCAAGAGGGGAGACATCAG 3’ 
ECM1 Ex 3 F 5’ GGCACTGTGGGCTCTGATGTCTCC 3’ ECM1 Ex 3 ECM1 Ex 3 R 5’ GGCCTCTTCCCTCCTTTCCACCTG 3’ 
ECM1 Ex 4 F 5’ TCAGGTGGAAAGGAGGGAAGA 3’ ECM1 Ex 4 ECM1 Ex 4 R 5’ TGAGGGCACCAAGGAGCAG 3’ 
ECM1 Ex 5 F 5’ CTCCCTCACCTCTATCCCACTATG 3’ ECM1 Ex 5 ECM1 Ex 5 R 5’ GAGCCCACCGTCTTGTCTGC 3’ 
ECM1 Ex 6pI F 5’ TCGCTTCTCTTTTCCTTTCAGTTA 3’ ECM1 Ex 6pI ECM1 Ex 6pI R 5’ AAGGCAGATTTGGTTCAGATTGT 3’ 
ECM1 Ex 6pII F 5’ GACCAGAGCCATCCAGAACC 3’ ECM1 Ex 6pII ECM1 Ex 6pII R 5’ CCCCCGGCATCAAGAAC 3’ 
ECM1 Ex 7pI F 5’ GCCAGGGGAGCAGAGGACAACC 3’ ECM1 Ex 7pI ECM1 Ex 7pI R 5’ GCGTGGCACAGAGCGGAAGC 3’ 
ECM1 Ex 7pII F 5’ CTCCCCAGCCACACTACCAG 3’ ECM1 Ex 7pII ECM1 Ex 7pII R 5’ GGACAGCCACAAGCAGATGA 3’ 
ECM1 Ex 8pI F 5’ TCTAGTTGCCAGGGACGATAAGG 3’ ECM1 Ex 8pI ECM1 Ex 8pI R 5’ CCGACGGGCAAAGCACTCAT 3’ 
ECM1 Ex 8pII F 5’ CTGTGACCGGGAGTATGCTGTG 3’ ECM1 Ex 8pII ECM1 Ex 8pII R 5’ TTCCCAAAGGTGTCCCAAAAG 3’ 
ECM1 Ex 9 F 5’ ATATCCCAACCCCATCTGA 3’ ECM1 Ex 9 ECM1 Ex 9 R 5’ AAAAACACCTCCCCCACTA 3’ 
ECM1 Ex 10 F 5’ CTCCCCACCCCATCATCTGTTTTA 3’ ECM1 Ex 10 ECM1 Ex 10 R 5’ GGCTCTGGGGTGACTCATTCTTCC 3’ 
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Table 2-6: dHPLC PCR conditions 
Marker Name Annealing Temperature Expected Product Size 
ECM1 Ex 1 66 oC 268bp 
ECM1 Ex 2 62oC 269bp 
ECM1 Ex 3 69oC 233bp 
ECM1 Ex 4 62oC 257bp 
ECM1 Ex 5 62.5 oC 251bp 
ECM1 Ex 6pI 59.6 oC 341bp 
ECM1 Ex 6pII 60.6 oC 330bp 
ECM1 Ex 7pI 69.3 oC 381bp 
ECM1 Ex 7pII 61.1 oC 400bp 
ECM1 Ex 8pI 64.4 oC 204bp 
ECM1 Ex 8pII 62.8 oC 266bp 
ECM1 Ex 9 55.7 oC 292bp 
ECM1 Ex 10 66.5 oC 286bp 
 
The resultant PCR product was then electrophoresed on a 2% agarose gel at 120V, with 
electrodes spaced 30cm apart for approximately 30 minutes and photographed under UV 
(260nm) light to confirm that the correct amplimer had been PCR amplified. 
 
 
 
 
Figure 2-4: Schematic representation of the expected ECM1 PCR products for exons one to ten run 
on a 2% agarose gel 
Lane 1: 1kb ladder, fragment sizes stated in Figure 2-1; Lanes 2 – 14: PCR products of ECM1 exons one to 
ten, with product sizes stated in Table 2-6, 1kb plus in lane 15. 
 
2.2.4.2 Denaturing high performance liquid chromatography (dHPLC) 
dHPLC is a simple and reliable technique that is based on the difference in retention time 
of the heteroduplexes and homoduplexes on a stationary phase or column. A homoduplex 
is defined as a stretch of dsDNA with both strands totally complimentary to each other, 
1         2          3          4          5          6          7         8          9        10       11        12        13      14      15 
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i.e. there is no miss-pairing. A heteroduplex is defined as a stretch of dsDNA with both 
strands being almost totally complimentary to each other, but with one or more miss-
pairing base pair. Homo- and heteroduplexes are formed by denaturing the dsDNA at 
95oC for five minutes to produce ssDNA. The ssDNA is then slowly cooled to 23oC over 
45 minutes to facilitate reannealing of the ssDNA. As all strands are either totally or 
almost totally complimentary to each other, they will re-anneal randomly, forming 
homoduplexes and heteroduplexes (Figure 2-5). Therefore, homoduplexes are formed 
when two identical amplimers are mixed and denatured. Heteroduplexes are formed when 
two similar but not identical amplimers are mixed and denatured. Similarly, 
homoduplexes can be formed when a single homozygous amplimer is denatured and 
heteroduplexes can be formed when a single heterozygous amplimer is denatured. 48 
 
 
Figure 2-5: Homoduplex and heteroduplex formation 
“Wild type” and “mutant” can be read as variant A and variant B 
 
The published DNA sequence of each amplimer from the UCSC genome browser was 
entered into the WAVEMAKER™ v.4.1 System software, which then calculated and set 
up the optimal analysis conditions (temperature and acetonitrile concentration) for each 
amplimer (Table 2-7). The Transgenomic WAVE® DNA fragment analysis system then 
automatically loaded the sample into the stationary phase which electrostatically bound 
the amplimer. This was done in a low-stringency mobile phase (low acetonitrile 
concentration). Within heteroduplexes, “bubbles” would be formed where there was 
miss-pairing. These “bubbles” decreased the binding affinity of the heteroduplexes 
(relative to the homoduplexes) to the stationary phase. The Transgenomic WAVE® DNA 
fragment analysis system would then initiate a stringency gradient (based on acetonitrile 
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concentration) which is ramped to a high concentration over time (Table 2-7). The 
increasing levels of acetonitrile would increasingly interfere with the bonds between the 
stationary phase and the amplimer, eventually dislodging it from the stationary phase. 
The amplimer would then pass through a UV detector set at 260nm, which detected the 
presence and quantity of DNA. The data from the UV detector was translated into a graph 
of retention time vs. absorbance level. 
 
As the heteroduplexes would bind less strongly to the stationary phase, they would be 
eluted off the stationary phase before the homoduplexes. This theoretically would result 
in four peaks being detected by the UV detector, with the two heteroduplexes forming the 
first two peaks and the homoduplexes forming the latter two peaks. However, this does 
not always occur as the difference between the retention time between the two 
heteroduplexes and similarly between the two homoduplexes is so slight that the two 
heteroduplexes elute at the same time and similarly with the homoduplexes. This gave 
rise to two peaks instead of the expected four. If there were two different variants within 
a specific exon, a sample with variant A would have a different retention time of the 
heteroduplexes and a different peak pattern when compared to a sample with variant B. 
 
 
Figure 2-6: dHPLC chromatogram showing a typical double peak pattern generated by heteroduplex 
and homoduplex elution off the stationary phase 
 
Each PCR primer pair was designed such that the expected amplimer size was 400bp or 
less. This was done because as one analyses larger amplimers, these amplimers tend to 
Heteroduplex peak Homoduplex peak Injection Peak Wash peak 
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contain clusters or “domains” that have a high GC content (guanine and cytosine 
residues). This forms areas within the amplimer that have a higher Tm than other areas 
with lower GC content. These GC rich domains increase the Tm needed to analyse the 
entire amplimer with dHPLC and this means that the domains with lower Tm's cannot be 
analysed as accurately as the domains with higher Tm's. Obviously, as the length of the 
amplimer increases, the larger the chance of having two or more domains with different 
Tm's. To avoid this, amplimers should be less than 400bp in length or alternatively the 
amplimer should be analysed a number of times, at each domain’s optimum Tm.48 This 
meant that exons six, seven and eight each were amplified using two overlapping PCR 
primer sets, named ECM1 Ex 6pI, ECM1 Ex 6pII, ECM1 Ex 7pI, ECM1 Ex 7pII, ECM1 
Ex 8pI and ECM1 Ex 8pII.  
 
Once the PCR product for dHPLC analysis was available, either one of two approaches 
was taken. Either the sample was mixed with an equal amount of a control homozygous 
sample (determined by dHPLC) or the sample was analysed alone. The former was done 
to identify homozygotes that were different from the known homozygote, while the latter 
was done to identify samples that were heterozygous only. Initially the mixing of the 
samples was done to identify all variants, that is, variants in both the heterozygous and 
homozygous states. However, the homozygous control sample was finished before the 
analysis could be completed, and the standard heterozygous detection method was 
employed on the remainder of the samples. This resulted in exons one through eight part 
one being analysed with the mixing method, while exons eight part two through ten were 
analysed with the non-mixing method. 
 
If the mixing method was to be used, each PCR product was electrophoresed on a 2% 
agarose gel to confirm that product was present. If the sample and the control PCR 
product were present, they were mixed in a one to one ratio and denatured. If the mixing 
method was not used, the samples were denatured without mixing. Once denatured and 
re-annealed, the samples were then loaded and analysed on the Transgenomic WAVE® 
DNA fragment analysis system with conditions stipulated in Table 2-7.  
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Table 2-7: dHPLC conditions for each ECM1 exon analysed 
Exon Oven Temperature (oC) 
Start 
Buffer B% 
End Buffer 
B% 
Time Shift 
(min) 
Exon 1 61.9 50 62 0 
Exon 2 62.0 50 62 0 
Exon 3 60.9 49 61 0 
Exon 4 62.4 50 62 0 
Exon 5 62.1 50 62 0 
Exon 6pI 58.4 52 64 0 
Exon 6pII 61.8 54 66 -1 
Exon 7pI 61.9 53 65 0 
Exon 7pII 62.3 56 68 -1 
Exon 8pI 62.2 47 59 0 
Exon 8pII 61.7 50 62 0 
Exon 9 59.6 51 63 0 
Exon 10 60.0 51 63 0 
 
Once each sample had been analysed on the Transgenomic WAVE® DNA fragment 
analysis system, the peak patterns were analysed for any double peaks or time shifts. 
Within each exon, the samples that showed variation were then analysed to see if they 
had the same peak retention time and peak pattern. It was assumed that if a certain 
sample showed a similar retention time and pattern to a second sample’s retention time 
and pattern, that these two samples contained the same variant. Therefore, one sample of 
each dHPLC pattern was sequenced to identify the variant. 
 
2.2.4.3 Sanger dideoxy DNA sequencing 
The Sanger dideoxy DNA sequencing method or cycle sequencing is a modified PCR 
technique that utilizes both fluorescently labelled dideoxynucleotides (ddNTPs) and 
unlabeled deoxynucleotides (dNTPs).43,49 The four different ddNTPs are each 
fluorescently labelled with a different fluorescent molecule, which will fluoresce a 
different colour when in the excited state. The ddNTPs each lack a free 3’ hydroxyl 
group, and hence when they are incorporated into a synthesizing strand, they terminate 
the synthesis of the strand because they lack the 3’ hydroxyl group that is needed to form 
a phosphodiester bond with the next dNTP (or ddNTP) 5’ phosphate group. Since both 
ddNTPs and dNTPs are present in the reaction mix, they compete for position in the 
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synthesizing strand, and are incorporated into it randomly, thereby generating strands of 
random length, each with a fluorescently labelled ddNTP attached to the 3’ end. 
 
In each cycle sequencing reaction, only one primer of a primer set is used and therefore 
two reactions are set up for each primer set, one containing only the forward primer, and 
the other containing only the reverse primer. This would generate a “forward” and a 
“reverse” sequence for the area that the primers flanked. In this way the forward and 
reverse sequences of each sample are comparable, and thereby confirm the obtained 
sequences.  
 
The PCR product to be sequenced was first purified using Nucleospin Extract columns 
according to the protocol in Appendix 5.2. The purified PCR product was then cycle 
sequenced twice, using the forward primer only and then the reverse primer only to 
generate forward and reverse sequence for each sample. The cycle sequencing was done 
using the Sanger dideoxy sequencing method, according to the protocol in Table 2-8. 
 
Table 2-8: Cycle sequencing reaction conditions 
Thermal Cycling 
Conditions 
Volume Description Stock Concentration 
5µl Purified PCR product N/A 
4µl Big Dye v.3.1 N/A 
1µl Primer 3.3pM 
4µl Big Dye v3.1 Buffer 2.5x 
6µl ddH2O N/A 
 
96oC → 30 seconds     
50oC → 15 seconds        25x         
60oC → 4 minutes 
24oC → hold 
20µl Total N/A 
 
 
Once the sample had been cycle sequenced, the resultant product was purified using 
SigmaSpin Post-Reaction Purification columns according to the protocol in Appendix 
5-3. These columns selectively remove small molecules such as unincorporated dyes, 
nucleotides and salts from the reaction, while maximizing the recovery of single and 
double stranded DNA molecules larger than 20bp.  The purified cycle sequenced product 
was then dried in a rotary evaporator in a vacuum. Once the sample has been dried, it was 
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resuspended in 2.5µl dextran-formamide dye and the sample was then loaded onto a 
denaturing 4.3% polyacrylamide gel and electrophoresed using the ABI 377 Sequencer. 
The raw fluorescent data was captured with the ABI 377 collection software v.2.1 and 
then analysed with the Sequencing Analysis v.3.4.1 software program. This generated an 
electropherogram, which represents the sequence of the sample that was cycle sequenced. 
The electropherogram was analysed with the sequence analysis software DNASTAR 
SeqManII. A variant was confirmed if it was seen in both forward and reverse 
sequence. 
 
2.2.5 Statistical Analyses 
2.2.5.1 Hardy-Weinberg equilibrium and carrier frequency calculations  
Hardy-Weinburg equilibrium assumes that the variant or mutation being investigated 
does not incur a selective advantage or disadvantage to an individual, and assumes that 
there is no migration, mutation or random genetic drift occurring in the population 
studied.50,51 This was assumed to be true for the Q276X mutation and the Namaqualand 
Coloured population of South Africa, as LP individuals generally have a normal life 
expectancy, and it is likely that negligible migration into or out of Namaqualand occurs. 
This may be because of the poor socio-economic status of the general Namaqualand 
population that was observed by ourselves on visiting the area.  
 
To assess whether the ECM1 genotype frequencies deviated from Hardy-Weinberg 
expectation in the Coloured population, the observed genotype frequencies were 
compared to expected genotype frequencies (predicted by the Hardy-Weinberg law from 
the sample allele frequencies). To ascertain significance, a Chi-squared test was then 
completed using the observed and expected values, as shown in Table 2-9. The expected 
values were calculated using the following equations: 
p + q = 1 
p2 + 2pq + q2 = 1 
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where 
p is the frequency of the non-Q276X allele 
q is the frequency of the Q276X allele 
p2 is the frequency of homozygous non-Q276X genotypes 
2pq is the frequency of the Q276X/non-Q276X heterozygous genotypes 
q2 is the frequency of homozygous Q276X genotypes 
 
If either p or q is known, then q or p can be estimated by p + q = 1. Hence p2, 2pq and q2 
can be estimated. 
 
Table 2-9: Chi-Squared calculation 
Genotype Observed (O) Expected (E) (O – E)2/E 
Non-Q276X homozygote x1 p2 (O – E)2/E 
Q276X heterozygote x2 2pq (O – E)2/E 
Q276X homozygote x3 q2 (O – E)2/E 
Total N N χ21 
   P 
N is the total number of individuals investigated, x1 to x3 are the observed numbers of non-Q276X 
homozygotes, Q276X heterozygotes and Q276X homozygotes respectively. 
 
If the P value is greater than 0.05, then the Q276X mutation in the Coloured population 
did not differ significantly from the expectations of Hardy-Weinberg equilibrium and the 
population was considered to be in Hardy-Weinberg equilibrium. The converse would be 
considered true if the P value was less than 0.05. 
 
2.2.5.2 Haplotype Estimation 
Where haplotypes could not be inferred from pedigrees, haplotypes and haplotype 
frequencies were estimated from genotypic data using the software program Arlequin 
v1.1 (Appendix 6.1 and 6.2)52. Arlequin uses an Expectation-Maximum (EM) algorithm 
to generate maximum-likelihood estimates of haplotype frequencies from the genotypic, 
phase unknown data.  
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The EM algorithm has the following steps: 
1) Start with random estimates of haplotype frequencies. 
2) Assuming Hardy-Weinberg equilibrium, use the above estimates to calculate 
expected genotype frequencies. This is the E step. 
3) The relative genotype frequencies are used as weights for their constituent 
haplotypes in a gene counting procedure. This leads to new haplotype frequency 
estimates. This is the M step. 
4) Steps two to three are repeated until the estimated haplotype frequencies reach 
equilibrium. 
 
This is a reasonable method for estimating haplotypes and their frequencies when phase 
cannot be determined from genotypic data. However, the EM method can erroneously 
estimate haplotypes and their frequencies. This can occur because there are theoretically 
many different haplotypes and haplotype frequencies at which the EM algorithm can 
reach equilibrium. To avoid this, Arlequin will try to identify the most likely haplotypes 
and frequencies (i.e. those that reach an equilibrium with the lowest variance). 
Alternatively, one could run the program many times and use the most common 
haplotypes that are estimated. This was not done here because of the computing time 
necessary to estimate the haplotypes in this study (~24 hours). 
 
2.2.5.3 Linkage disequilibrium 
Linkage disequilibrium (LD) is a term used to describe a scenario where two alleles at 
different loci are associated with each other more often than the population frequencies of 
those alleles would predict.49 For example, if in a population (in Hardy-Weinberg 
equilibrium) there were two loci, A and B, each with alleles 1 and 2 with the frequencies: 
A1: 0.4 B1: 0.7 
A2: 0.6 B2: 0.3 
The predicted frequency of haplotype A1 B2 in that population would be                       
0.4 x 0.3 = 0.12. If the observed frequency of A1 B2 was 0.8, that would show that there 
was a discrepancy between the observed and expected frequencies. If this was a 
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significant discrepancy and hence chance could be ruled out, then the alleles A1 and B2 
could be said to be in LD. If not, then they could be said to be in linkage equilibrium, 
where the observed frequencies do not significantly differ from the expected frequencies. 
 
LD within the random Coloured, random White, Coloured LP and White LP groups was 
investigated with the D’ statistic calculated using Arlequin v1.1.52 Additionally, LD was 
calculated in the Coloured LP and White LP groups using the δ statistic, as described by 
Devlin and Risch.53 This was determined to be either significant or not using the Fisher’s 
Exact test and the χ
2
 test, respectively.  
 
2.2.5.3.1  D’ Analysis 
D’ refers to the decimal fraction of the LD (D) relative to the maximum possible LD 
(Dmax) for the observed frequencies present. Traditionally D’ is calculated using the 
equation D/Dmax. As this is tedious for large data sets, the computer program Arlequin 
v1.1 was employed to calculate the D’ statistic. Observed haplotypic data was used where 
possible, however, in the random samples pedigree information was not available and 
estimated haplotypes were then used. 
 
In order to use the D’ statistic, a contingency table is needed to estimate haplotype 
frequencies, as shown in table 2-11 for a 2x2 contingency table. However, in order to do 
this, an initial contingency table must be constructed with the observed numbers of alleles 
(Table 2-10). In this study, the disease allele was the Q276X mutation and the normal 
allele was any allele without the Q276X mutation. Two groups were used to construct 
this table: the LP group (Coloured or White) and a random control group (Coloured or 
White, respectively). The LP group information was entered only into the disease allele 
column, while the control group information was entered only into the normal allele 
column. 
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Table 2-10: Layout and notation for a 2x2 contingency table for use in haplotype frequency 
estimation 
Marker Disease Allele Normal Allele Total 
A1 n11 n12 n1+ 
A2 n21 n22 n2+ 
Total n+1 n+2 n 
 
A1 is the allele suspected to be associated with the disease allele while A2 is any other 
allele other than A1. n11 is the number of observed A1-Disease allele haplotypes, n12 is 
the number of observed  A1-Normal haplotypes, n21 is the number of observed A2-
Disease haplotypes and n22 is the number of observed  A2-Normal haplotypes. n+1 and n+2 
are the sums of their respective columns while n1+ and n2+ are the sums of  their 
respective rows. n is the sum of n+1, n+2, n1+ and n2+. 
 
Table 2-11: Layout and notation for a 2x2 contingency table for use in δ calculation 
 Disease Allele Normal Allele Total 
A1 pi11 pi 12 pi 1+ 
A2 pi
 21 pi 22 pi 2+ 
Total pi
 +1 pi +2 1(pi) 
 
pi11, pi21, pi12 and pi22 are estimated frequencies estimated from Table 2-10.  
pi11 = n11/n 
pi12 = n12/n 
pi21 = n21/n 
pi22 = n22/n 
 
pi+1 and pi+2 are the sums of their respective columns while pi1+ and pi2+ are the sums of 
their respective rows. pi is the sum of pi+1, pi+2, pi1+ and pi2+, and by definition, pi should 
always add up to 1. 
 
D’ was calculated using the equation D’ = (pi11pi22 – pi12pi21)/(pi+1pi2+) for each allele of each 
marker and LD is scored between markers and not alleles. As this is a tedious calculation, 
the software program Arlequin was employed for these calculations. 
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2.2.5.3.2 δ Analysis 
δ is calculated according to the equation δ = (pi11pi22 - pi12pi21)/(pi+1pi22) and was calculated 
in this fashion for the most common allele of each marker in both LP groups. The δ was 
used as it is more robust in case-control scenarios than D’ is,53 and the calculation here 
was employed to compare Q276X homozygotes with non-Q276X homozygotes. 
 
2.2.5.3.3 dHPLC Analysis 
 
Raw data from dHPLC analysis was scored as to the presence of heteroduplexes or 
homoduplexes. This was then summarised into a table as shown in table 2-12 and 
significant deviation from the null hypothesis (all three samples are from the same 
population) was tested for using the Chi squared test using two degrees of freedom.54  
 
Significance was taken at the 5% significance level (α = 0.05), which was then adjusted 
to a table wide significance level55 (table wide significance level = α/k, where k = the 
number of comparisons being made). In this case k = 6 (three population groups and two 
data groups, namely heteroduplexes and homoduplexes) and therefore P must be less than 
or equal to α/k (0.05/6 = 0.0083) to be significant at the 5% significance level. 
 
Additionally, heteroduplex dHPLC data for each sample population was compared to the 
other sample populations. Heteroduplex dHPLC data was summarised for the Random 
Black, Random Coloured and Random White sample populations as shown in Table 2-
13. 
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Table 2-12:  Example χ2 calculation for dHPLC results for an individual exon 
Observed 
 Heteroduplexes Homoduplexes Total 
Random Black 
group Observed number Observed number Row Total (R1) 
Random Coloured 
group Observed number Observed number Row Total (R2) 
Random White 
group Observed number Observed number Row Total (R3) 
Total Column Total (C1) Column Total (C2) Grand Total (N) 
Frequency Column frequency (C1/N) 
Column frequency 
(C2/N) Total Frequency (1) 
Expected 
Random Black 
group (C1/N)xC1 (C2/N)xC2 R1 
Random Coloured 
group (C1/N)xC1 (C2/N)xC2 R2 
Random White 
group (C1/N)xC1 (C2/N)xC2 R3 
Total Column Total (C1) Column Total (C2) Grand Total (N) 
Chi squared (χ2) Calculation 
Random Black 
group 
(Observed number – 
Expected 
number)2/(Expected 
number) 
(Observed number – 
Expected 
number)2/(Expected 
number) 
 
Random Coloured 
group 
(Observed number – 
Expected 
number)2/(Expected 
number) 
(Observed number – 
Expected 
number)2/(Expected 
number) 
 
Random White 
group 
(Observed number – 
Expected 
number)2/(Expected 
number) 
(Observed number – 
Expected 
number)2/(Expected 
number) 
 
 
χ2 = The sum of all six blocks P = χ2 value with two degrees of freedom 
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Table 2-13: Example table for calculating population pairwise χ2 results for each of ECM1 exons 
Exon Random Population Sample 1 Random Population Sample 2 
Exon 1 OH OH 
Exon 2 OH OH 
Exon 3 OH OH 
Exon 4 OH OH 
Exon 5 OH OH 
Exon 6 OH OH 
Exon 7 OH OH 
Exon 8 OH OH 
Exon 9 OH OH 
Exon 10 OH OH 
OH indicates observed heteroduplexes. 
 
Population Sample 1’s observed heteroduplexes for each exon were used as the observed 
numbers and Population Sample 2’s observed heteroduplexes for each exon were used as 
the expected numbers in a Chi squared test with one degree of freedom. A significance 
level of 5% (α = 0.05) was used. This was adjusted to table wide significance levels by 
using k = 2, i.e. a sample was only significant at the 5% level if the P value was less than 
or equal to 0.025 (α /k = 0.05/2). 
 
2.3 Data integrity 
In an attempt to minimize errors, raw BfaI, microsatellite, dHPLC and sequence data was 
analysed and corroborated by at least one colleague from the Human Molecular Genetics 
laboratory. Where discrepancies were found the sample was either re-analysed or 
changed to the new value after discussion. 
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CHAPTER 3 RESULTS 
 
3.1 Q276X mutation screening 
In total, 170 individuals were tested for the Q276X mutation by PCR amplifying exon 
seven of the ECM1 gene and digesting the resultant amplimer with the BfaI restriction 
endonuclease. The 170 individuals were comprised of 36 South African LP individuals 
(29 Coloured and seven White) and 33 members of their immediate family (28 Coloured 
and five White), 100 random Coloured control individuals from Namaqualand and one 
Black non-LP individual. The Black individual was referred to us because of a diagnosis 
of epilepsy and chronic hoarseness. This individual was included in this study to exclude 
a diagnosis of LP at the molecular level for this individual. Figure 3-1 shows a typical 
result following BfaI digestion. 
 
 
Figure 3-1: Agarose gel showing ECM1 exon seven PCR products digested with the BfaI restriction 
endonuclease. 
Lane 1 contains the 1kb size standard. Three controls were used on this gel, a known Q276X homozygote 
(Lane 2), an undigested control (Lane 3) and a digested sample with no DNA or ‘Blank” (Lane 13). Lanes 
4, 8, 9 and 12 show the typical Q276X/Q276X homozygote digestion pattern. Lanes 5 – 7 and 10 show the 
typical Q276X/WT heterozygote digestion pattern, while lane 11 shows the WT/WT homozygote digestion 
pattern. Fragment sizes are shown in Figure 2-1. 
 
All 36 LP individuals were found to be homozygous for the Q276X mutation and all 
parents of LP children (obligate heterozygotes) were found to be heterozygous for the 
Q276X mutation. This provides strong evidence for the suspected founder effect for LP 
1        2         3         4         5        6     7         8         9        10      11       12       13 
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in South Africa, however further investigation is needed. The Q276X mutation may have 
arisen multiple times due to recurrent mutations. To provide further support that the 
Q276X mutation arose once within the South African population either by a single 
founder, a founder family or mutation, and hence that the high frequency achieved by the 
mutation Q276X is due to a founder effect, haplotype analysis of LP individuals is 
needed. 
 
3.1.1 The Q276X mutation in the Namaqualand population 
Within the 100 random Coloured controls tested for the Q276X mutation, 11 were found 
to be carriers of the Q276X mutation, making the carrier frequency one in nine 
individuals in the Namaqualand region of South Africa (ƒ = 11/100 = 0.11, 11:100 ≈ 1:9). 
Assuming Hardy-Weinberg equilibrium, the Q276X allele frequency (q) is therefore 
0.055 (Table 3-1) and gives an estimated incidence of LP homozygotes of one in every 
370 births (q = 0.055, incidence  = (2pq)2 × 0.25). 
 
Table 3-1: Observed allele frequencies (p and q) and estimated genotype frequencies (p2, q2 and 2pq) 
for the Q276X and wild type (WT) alleles in the random Namaqualand population (N = 100) 
Allele/Genotype Variable Value 
WT allele frequency p 89/200 (0.945) 
Q276X allele frequency q 11/200 (0.055) 
WT homozygote frequency p2 0.9452 (0.893) 
WT/Q276X heterozygote frequency 2pq 2 × 0.945 × 0.055 (0.104) 
Q276X homozygote frequency q2 0.0552 (0.003) 
 
The Q276X mutation was not significantly different from the expectations of Hardy-
Weinberg equilibrium (χ21= 0.339, P = 0.591) in the Coloured population of 
Namaqualand (Table 3.2). 
 
Table 3-2: χ21 investigation of the Q276X mutation within the Coloured population 
Genotype  Observed (O) Expected (E) (O-E)2/E 
WT/WT 89 (0.890) 89.303 0.001 
Q276X/WT 11 (0.110) 10.395 0.035 
Q276X/Q276X 0 (0.000) 0.302 0.302 
Total 100.000 100.00 χ21 = 0.339 
 
  P = 0.591 
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3.2 Linked markers analysis 
Four linked microsatellite dinucleotide markers: ND1, D1S2343, D1S305 and D1S2624, 
which together span 9.98Mb around the ECM1 gene, were investigated. These markers 
were typed in all LP patients (29 Coloured and seven White), their first-degree family 
members where available (28 Coloured and five White), 50 random Coloured controls 
and 30 random White controls.  
 
For marker ND1, a repeat number of 19 was correlated with a fragment size of 219bp, a 
fragment size of 250bp for marker D1S2343 was correlated with a repeat number of 12, a 
fragment size of 177bp was correlated with a repeat number of 23 for D1S305 and a 
fragment size of 347bp was correlated with a repeat size of 22 for marker D1S2624 
(Figures 3-2 to 3-5). Sizes were calculated relative to the 500 Rox Size Standard that 
was loaded into each lane with sample. 
 
3.2.1 Microsatellite Analysis 
 
Figure 3-2: Electropherogram of the ND1 dinucleotide microsatellite marker showing an individual 
homozygous for the 19 repeat allele.  
X axis: Fragment size in bp, estimated from the internal 500 Rox Size Standard. Y axis: Fluorescence 
intensity. 
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Figure 3-3: Electropherogram of the D1S2343 dinucleotide microsatellite marker showing an 
individual homozygous for the 12 repeat allele 
X axis: Fragment size in bp, estimated from the internal 500 Rox Size Standard. Y axis: Fluorescence 
intensity. 
 
 
Figure 3-4: Electropherogram of the D1S305 dinucleotide microsatellite marker showing an 
individual homozygous for the 23 repeat allele 
X axis: Fragment size in bp, estimated from the internal 500 Rox Size Standard. Y axis: Fluorescence 
intensity. 
 
 
Figure 3-5: Electropherogram of the D1S2624 dinucleotide microsatellite marker showing an 
individual homozygous for the 22 repeat allele 
X axis: Fragment size in bp, estimated from the internal 500 Rox Size Standard. Y axis: Fluorescence 
intensity. 
 
 
A summary of all the microsatellite marker results is in Appendix 5.4. Each microsatellite 
marker was highly polymorphic in both the random Coloured and random White 
populations (Table 3-3), and the observed heterozygosity was very similar between the 
two population groups analysed. 
 
 46 
Table 3-3: Observed heterozygosity in the random Namaqualand and random White populations 
Marker 
Random Coloured 
population observed 
heterozygosity 
Random White population 
observed heterozygosity 
ND1 0.74 0.67 
D1S2343 0.86 0.87 
D1S305 0.90 0.93 
D1S2624 0.75 0.77 
 
When the random population allele frequencies are compared with the allele frequencies 
observed in LP patients, a striking difference is seen (Figures 3-6 to 3-9). This is 
attributed to the high number of LP patients who are homozygous for the particular allele. 
The common LP alleles are allele 19 in the ND1 marker system, allele 12 in the D1S2343 
marker system, allele 23 in the D1S305 marker system and allele 22 in the D1S2624 
marker system. 
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Namaqualand Coloured
LP patients (N = 29)
 
Figure 3-6: Histogram showing the allele frequencies for marker ND1 in the four groups analysed 
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D1S2343 allele frequencies
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Figure 3-7: Histogram showing the allele frequencies for marker D1S2343 in the four groups 
analysed 
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Figure 3-8: Histogram showing the allele frequencies for marker D1S305 in the four groups analysed 
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Figure 3-9: Histogram showing the allele frequencies for marker D1S2624 in the four groups 
analysed 
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3.2.2 Haplotype analysis 
Pedigrees were compiled for the LP patients and their family members (Appendix 5.5). 
Haplotypes were deduced since phase could be determined in most of these pedigrees, 
(Table 3-6). As family data was not available for the random Coloured and random White 
groups, haplotypes were estimated using the software program Arlequin (Appendix 5.6 
and Appendix 5.7). Due to restrictions of analysis with Arlequin, ECM1 mutation status 
could not be included in the haplotype estimation, as the Q276X mutation is a single 
nucleotide variant, and cannot be included in microsatellite analysis.  
 
When the alleles are compiled into haplotypes, a striking founder haplotype was seen in 
both the Coloured and White LP patients (Table 3-6), while in first-degree family 
members there were very few common haplotypes seen (Table 3-7). Where there were 
affected siblings, only one affected individual per family was included in the analysis. 
The most common haplotype seen, and the haplotype most likely to be the founder 
haplotype, is 19-12-23-22 (ND1-D1S2343-D1S305-D1S2624), or haplotype LPh1. 
 
Table 3-4: ECM1-associated haplotypes in 24 (n=48) unrelated Coloured LP patients from 
Namaqualand and six (n = 12) unrelated Caucasoid LP patients. Conserved haplotypes are in shaded 
areas.  
Haplotype 
Number 
Number of 
Haplotypes 
ND1 
Alleles 
ECM1 
Q276X 
D1S2343 
Alleles 
D1S305 
Alleles 
D1S2624 
Alleles 
NAMAQUALAND COLOURED LP HAPLOTYPES 
LPh1 34 19 Y 12 23 22 
LPh2 6 19 Y 12 23 23 
LPh3 2 19 Y 12 23 20 
LPh4 2 19 Y 12 18 22 
LPh5 1 19 Y 12 23 18 
LPh6 1 19 Y 12 19 22 
LPh7 1 19 Y 12 26 23 
LPh8 1 14 Y 12 23 22 
SOUTH AFRICAN WHITE LP HAPLOTYPES 
LPh1 8 19 Y 12 23 22 
LPh9 2 17 Y 12 23 18 
LPh10 1 15 Y 12 23 20 
LPh11 1 22 Y 12 23 22 
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A core haplotype of 19-12  (ND1-D1S2343), spanning 4.87Mb around ECM1, was 
present in 92% of the LP haplotypes (98% of the Coloured LP haplotypes and 67% of the 
White LP haplotypes). 
 
Table 3-5: ECM1-associated haplotypes from non-Q276X alleles deduced from unaffected Coloured 
(n = 26) and White first degree family members (n = 5). Haplotype similar to the founder haplotype 
is shaded. 
Haplotype 
Number 
Number of 
Haplotypes 
ND1 
Alleles 
ECM1 
Q276X 
D1S2343 
Alleles 
D1S305 
Alleles 
D1S2624 
Alleles 
NAMAQUALAND COLOURED HAPLOTYPES 
Ph1 2 17 N 26 26 23 
Ph2 2 21 N 18 27 20 
Ph3 1 15 N 21 19 19 
Ph4 1 16 N 17 19 19 
Ph5 1 17 N 12 19 20 
Ph6 1 17 N 12 21 20 
Ph7 1 17 N 12 22 18 
Ph8 1 17 N 12 24 18 
Ph9 1 17 N 17 23 18 
Ph10 1 17 N 18 23 22 
Ph11 1 17 N 18 23 23 
Ph12 1 17 N 19 18 19 
Ph13 1 17 N 20 19 22 
Ph14 1 17 N 20 23 20 
Ph15 1 17 N 20 24 22 
Ph16 1 17 N 21 18 21 
Ph17 1 18 N 18 26 20 
Ph18 1 18 N 20 23 20 
Ph19 1 18 N 22 19 23 
Ph20 1 18 N 22 19 20 
Ph21 1 19 N 20 23 20 
Ph22 1 20 N 18 20 19 
Ph23 1 20 N 19 18 21 
Ph24 1 23 N 19 23 18 
SOUTH AFRICAN WHITE HAPLOTYPES 
Ph25 1 17 N 12 22 22 
Ph26 1 17 N 19 18 18 
Ph27 1 19 N 19 21 22 
Ph28 1 19 N 12 23 19 
Ph29 1 21 N 19 21 22 
 
Within the haplotypes estimated by Arlequin (Appendix 5.6) for both the random 
Coloured and White populations, only one of the 124 (81 Coloured and 43 White) 
 50 
estimated haplotypes showed similarity to the founder haplotype. This was found within 
the random Coloured population and was 19-12-23-23 and is only one mutational step 
away from the founder haplotype of 19-12-23-22. 
 
3.2.3 Linkage Disequilibrium (LD) Analysis 
3.2.3.1 D’ Analysis 
In order to compare LD between the four different groups (namely the Coloured LP 
patients, White LP patients, Random Coloured population and random White 
population), D’ was calculated with Arlequin v1.1 using haplotypic data only. Table 3-8 
summarizes the D’ results. Where two or more siblings were affected with LP, data from 
only one was taken so as not to artificially inflate LD associated with that particular 
haplotype common to both siblings. 
 
Table 3-6: Pairwise locus D' estimation of LD in the Coloured and White populations using 
haplotypic data 
Locus ND1 D1S2343 D1S305 D1S2624 
A B A B A B ND1 * C D C D C D 
A B A B D1S2343 * C D C D 
A B D1S305 * C D 
D1S2624 
 
 
 * 
A: Coloured LP patients, B: White LP patients, C: Random Coloured population, D: Random White 
population. Red squares indicate significant D’ LD (P < 0.05), Green squares indicate borderline 
significance D’ LD (0.10 > P > 0.05) and white squares indicate no significant D’ LD (P > 0.10). P values 
were calculated using the Fisher’s exact test. 
 
As can be seen in Table 3-8, each locus in both LP groups is in significant LD with each 
other, while only D1S2343 and D1S2624 are in significant LD with each other in the 
random Coloured population. The rest of the markers in the random Coloured population 
and all of the markers in the random White population are not in significant LD with each 
other (P > 0.05). As would be expected, the smaller, more consanguineous Coloured 
population showed more LD than the larger, less consanguineous White population. 
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3.2.3.2 δ analysis 
In order to estimate LD between the Q276X mutation and each allele of the founder 
haplotype (LPh1) in the Coloured and White LP patient groups, the δ statistic was used. 
This was then investigated for significance with the χ2 test with one degree of freedom. If 
the χ21 test produced a P value less than 0.05, that was then taken as a significant result. 
Table 3-9 summarizes the δ results obtained. 
 
Table 3-7: Summary of the LD results between each marker and the Q276X mutation from the 
Coloured and White LP patients 
 Coloured LP patients White LP patients 
Locus δ P δ P 
ND1 
Allele 19 0.98 1.84 x 10
-28 0.71 8.41 x 10-12 
D1S2343  
Allele 12 1.00 7.10 x 10
-27 1.00 8.11 x 10-7 
D1S305  
Allele 23 0.87 6.10 x 10
-16 1.00 1.73 x 10-7 
D1S2624 
Allele 22 0.78 2.30 x 10
-18 0.67 7.82 x 10-6 
 
Using the δ statistic, it was seen that there is strong LD between each allele of the 
founder haplotype and the Q276X mutation in both the Coloured and White LP groups.  
 
The microsatellite marker results, haplotype results and LD results indicate that the 
Q276X mutation is likely to have arisen only once on the LPh1 haplotype background. 
This is strong molecular evidence that the high incidence of LP in South Africa is due to 
a founder effect and not due to recurrent mutation.  
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3.3 Screening of the ECM1 gene for polymorphisms 
3.3.1 dHPLC analysis 
In order to identify the most common variants within ECM1, 60 random individuals, 20 
individuals each from three distinct populations (the South African Black population, the 
Namaqualand Coloured population and the South African White population) were 
analysed with dHPLC. Each exon was optimised for PCR and the expected fragment 
sizes, as illustrated in Figure 2-4, were obtained. Once PCR optimisation was completed, 
then dHPLC conditions were optimised for each PCR product, a summary of which can 
be seen in Table 2-7. Once the dHPLC system was fully optimised, either a mixing or a 
non-mixing method was followed. The mixing method was used for exons one through to 
eight pI, and exons eight pII to ten were analysed with the non-mixing method. 
 
The screening of the ECM1 gene with dHPLC resulted in the identification of many 
potential variants (Appendix 5.8). The frequencies of all individuals with variants seen 
per ECM1 exon were calculated, and investigated for significance using the χ2 
calculation, with the null hypothesis stating that there was no difference between the 
three populations. As an example, the results for exon three are shown on the following 
page (Table 3-10, Figure 3-10).  
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Table 3-8:  Example χ2 calculation for dHPLC results from ECM1 exon three 
Observed 
 Heteroduplexes Homoduplexes Total 
Observed in the 
random Black 
group 
0 (0.00) 20 (1.00) 20 
Observed in the 
random Coloured 
group 
1 (0.05) 19 (0.95) 20 
Observed in the 
random White 
group 
11 (0.55) 9 (0.45) 20 
Total 12 48 60 
Frequency 0.20 0.80 1 
Expected 
Expected in the 
random Black 
group 
4 (0.2) 16 (0.80) 20 
Expected in the 
random Coloured 
group 
4 (0.20) 16 (0.80) 20 
Expected in the 
random White 
group 
4 (0.20) 16 (0.80) 20 
Total 12 48 60 
Chi squared (χ2) Calculation 
(O-E)2/E (Random 
Black group) 4.000 1.000  
(O-E)2/E (Random 
Coloured group) 2.250 0.563  
(O-E)2/E (Random 
White group) 12.250 3.063  
 
χ22 = 23.125 P = 9.516 × 10-6 
 
When exon ten was analysed in this manner, the observed and hence expected values for 
heteroduplexes was zero. This became a problem when calculating the χ2 values, as the 
equation was divided by the number of expected heteroduplexes. As the expected number 
of heteroduplexes was zero, this gave an undefined result. Therefore, to avoid this, all 
observed values for exon ten were adjusted to 1. 
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Figure 3-10: dHPLC heteroduplex frequencies identified per ECM1 exon.  
χ2 P values with two degrees of freedom are shown above each exon 
 
Table 3-9: Summary of population pairwise χ21 results for each of ECM1 exons 
 Random Black 
group vs. random 
White group 
Random Black 
group vs. random 
Coloured group 
Random White 
group vs. random 
Coloured group 
Exon 1 - ++ - 
Exon 2 - - - 
Exon 3 +++ - +++ 
Exon 4 - - - 
Exon 5 - - - 
Exon 6 - - - 
Exon 7 - - - 
Exon 8 + - - 
Exon 9 - ++ - 
Exon 10 - - - 
- indicates no significant difference, + indicates significant difference at P < 0.05, ++ indicates significant 
difference at P < 0.01 and +++ indicates significant difference at P < 0.001. Significance levels were 
adjusted to table wide significance levels.55 Where undefined results were obtained, the expected values 
were adjusted to from zero to one. 
 
As can be seen in Figure 3-10, only exon three shows significant differences between all 
three populations, while pairwise analysis between each population (Table 3-9) of exons 
one, three, eight and nine showed significant difference. However, these results must be 
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interpreted with caution, as the sample size used for each population was very small  (N = 
20).   
 
Interestingly, exons three and seven in the White population show heteroduplex 
frequencies greater than 0.5. The theoretical maximum heteroduplex (heterozygote) 
frequency obtainable should be 0.5, where q = p = 0.5 and hence 2pq = 0.5 (Figure 3-11).  
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Figure 3-11: Estimated heteroduplex frequencies detected by the mixing method and non-mixing 
method graphed against varying frequencies of p (common allele frequency) 
 
The mixing method was used to identify variants in exons three to eight pI, and this must 
be taken into account. Assuming two alleles (p and q) at one locus and Hardy-Weinberg 
equilibrium, the non-mixing would detect only individuals in the heterozygous form 
(2pq), while the mixing method would detect individuals in the heterozygous form and in 
the rarer homozygous form (2pq + q2), assuming that q is the rarer allele and the control 
homozygote is homozygous for the common allele (p). Therefore the maximum 
detectable heteroduplex frequency using the mixing method is 0.75 (p = 0.5 and q = 0.5, 
Figure 3-11). This could explain the observed frequencies of greater than 0.5 in exons 
three and seven. Additionally, there could be more than one variant locus within the 
amplimer analysed, leading to an observed heteroduplex frequency of greater than 0.5. 
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Due to random genetic drift and different population histories, one would expect to see 
differences in heteroduplex frequencies (not necessarily significant) between different 
populations. However in exons six and seven, very similar heteroduplex frequencies were 
seen. This is likely to be due to chance. 
 
Interestingly, no variation was observed in exon ten, suggesting that there are no common 
variants in this exon. This was unexpected and may point to some form of selection 
acting on exon ten. This however did not explain the absence of synonymous variants or 
intronic variation. Again, random genetic drift, leading to fixation of alleles is the most 
likely explanations for this observation. 
 
3.3.2 Direct dideoxy sequencing 
Exons two to six were investigated with sequencing, and only one representative sample 
was sequenced of each heteroduplex pattern. Therefore, all individuals showing variation 
were not confirmed by DNA sequencing, and hence the accuracy of the detection of 
variants by dHPLC cannot be assessed here. 
 
A summary of all variants examined by DNA sequencing is given in Table 3-10 and the 
actual sequence electropherograms together with dHPLC chromatograms of the 
sequenced variants are shown in Figures 3-12 to 3-19. 
 
Table 3-10: Summary of variation found within the ECM1 gene 
Exon/Intron Variation seen Amino acid change 
Intron 1 nt 1314 C→T N/A 
Intron 1 nt 1400 C→T N/A 
Intron 2 nt 1486 G→A N/A 
Intron 3 nt 1673 A→G N/A 
Exon 4 nt 1823 C→T P77P 
Exon 5 nt 2057 C→T H122H 
Intron 5 nt 2655 C→A N/A 
Exon 6 nt 2773 C→T T130M 
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Figure 3-12: nt 1314 C→T  dHPLC heteroduplex chromatogram. Inset is nt 1314 C→T heterozygote 
reverse sequence electropherogram. The red arrow indicates the position of the variant 
 
 
Figure 3-13: nt 1400 C→T dHPLC heteroduplex chromatogram. Inset is nt 1400 C→T heterozygote 
forward sequence electropherogram. The red arrow indicates the position of the variant 
 
 
Figure 3-14: nt 1486 G→A dHPLC heteroduplex chromatogram. Inset is nt 1486 G→A heterozygote 
reverse sequence electropherogram. The red arrow indicates the position of the variant 
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Figure 3-15: nt 1673 A→G dHPLC heteroduplex chromatogram. Inset is nt 1673 A→G heterozygote 
reverse sequence electropherogram. The red arrow indicates the position of the variant 
 
 
Figure 3-16: nt 1823 C→T dHPLC heteroduplex chromatogram. Inset is nt 1823 C→T heterozygote 
forward sequence electropherogram. The red arrow indicates the position of the variant 
 
Figure 3-17: nt 2057 C→T dHPLC heteroduplex chromatogram. Inset is nt 2057 C→T heterozygote 
forward sequence electropherogram. The red arrow indicates the position of the variant 
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Figure 3-18: nt 2655 C→A dHPLC heteroduplex chromatogram. Inset is nt 2655 C→A heterozygote 
forward sequence electropherogram. The red arrow indicates the position of the variant 
 
 
Figure 3-19: nt 2773 C→T dHPLC heteroduplex chromatogram. Inset is nt 2773 C→T heterozygote 
forward sequence electropherogram. The red arrow indicates the position of the variant 
 
As can be seen in figures 3-12 to 3-19, each heteroduplex chromatogram shows a 
different retention time and peak pattern, albeit the differences are small. This showed 
that dHPLC was a useful method for detecting variation in PCR amplimers, but that it 
was not specific enough to qualify what the variation was. To identify the variant, a 
method such as endonuclease digestion or direct DNA sequencing would be needed. 
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CHAPTER 4 DISCUSSION 
 
The relatively common occurrence of LP in South Africa can now be reasonably 
explained as the result of a founder effect within the Namaqualand Coloured population 
and White population of South Africa. The presence of the Q276X mutation in the 
homozygous state in all affected individuals and in the heterozygous state in all obligate 
heterozygotes, the presence of a single founder haplotype, the presence of four 
microsatellite markers (spanning 9.98Mb around the ECM1 gene) in highly significant 
LD with the Q276X mutation in LP patients and the genealogical studies conducted by 
Gordon and Heyl,10-13,20 together leaves little doubt of the LP founder effect in South 
Africa. 
 
4.1 The Q276X mutation in South Africa 
It is unknown when LP was first diagnosed in South Africa, but the Q276X mutation is 
hypothesised to have been introduced into the South African population with the first 
Caucasian settlers in 1652 or shortly thereafter.10 Interestingly, the Q276X mutation has 
not yet been found in any other population than the South African population (I. Chan, 
personal communication), but it has been traced to the early German settlers of South 
Africa. The Q276X mutation has however not been found in Germany, or any other 
European country, although a cell line developed from a German LP patient has been 
identified (Coriell Cell Repositories, 
http://locus.umdnj.edu/nigms/nigms_cgi/display.cgi?GM13241). This cell line has not yet 
been investigated for the Q276X mutation. German LP patients have not been 
documented in the literature, and it may be that the Q276X mutation or any other LP 
mutations are rare within that population. Therefore, it would be interesting to search the 
German population for LP individuals and to test them for the Q276X mutation. 
 
When exactly the Q276X mutation occurred is unclear, but from the South African 
founder effect it is likely that the mutational event occurred outside South Africa, in 
Gerrit and Elsje Cloete’s paternal or maternal line and was passed on through them to 
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their descendants. As the number of descendants from Gerrit and Elsje Cloete increased, 
so the frequency of the Q276X mutation increased. This increased the likelihood of any 
random couple within South Africa conceiving a child affected with LP. The result of 
which is that today, the estimated incidence of LP in the Coloured Namaqualand 
population the estimated incidence is 1 in 370 live births. 
 
Within the Coloured Namaqualand population, the estimated carrier rate of the Q276X 
mutation is remarkably high (1 in 9). A founder effect can be considered to be the main 
reason for the high prevalence of the Q276X mutation within this population. This is 
compounded in the Namaqualand Coloured population because it is very small (~100 000 
individuals, www.statssa.gov.za). In light of these factors, genetic drift would have a 
powerful affect on the Coloured population of Namaqualand. Also, this population is 
divided into many small towns that are separated, in many cases, by large distances. This 
would limit the amount of migration between towns and this is likely to increase the 
number of intermarriages within families. This would increase the number of loci that are 
identical by descent, and elevate the chance of obtaining a double dose of the Q276X 
mutation. To further compound this issue, the general population of Namaqualand is very 
underprivileged. Therefore it is very hard for these people to migrate out of the 
Namaqualand area as their situation makes it very difficult to obtain good employment or 
to attend tertiary education institutions. Also, Namaqualand is not a highly 
commercialised or industrialized region of South Africa, with two thirds of the labour 
market either unemployed or not economically active (www.statssa.gov.sa, 2001 census). 
As a result of this, very little immigration into Namaqualand is likely to occur, and 
consequently there will be very little gene flow entering the Namaqualand population, 
allowing the Q276X mutation frequency to remain high in this population. 
 
The Q276X mutation results from a C to T transition at position 3468 within exon seven 
of ECM1. This changes a CAG codon (Glutamine) to a TAG codon (Stop) and hence 
results in the premature termination of the ECM1a and c protein isoforms, but not the b 
isoform. Treatment aimed at inducing the removal of or splicing out of exon seven is not 
likely to succeed as this happens ubiquitously in the skin of LP individuals due to 
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alternative splicing (ECM1b). As ECM1b does not rescue the LP phenotype, ECM1a is 
most likely the more biologically active and important isoform of ECM1. LP must 
therefore be caused by perturbation of expression of ECM1a. Symptomatically, LP 
presents with excessive scarring of the skin and hence ECM1a must play an important 
role in minimising scar formation or in proper scar healing. Therefore ECM1a presents 
itself here for potential use as an anti-scarring medication and could be used perhaps as a 
topical cream, especially on burn victims and on patients to reduce post-operative scars.  
 
4.2 The LP founder haplotype 
The LP founder haplotype (LPh1) 19-12-23-22 (ND1-D1S2343-D1S305-D1S2624) was 
very common in the LP groups studied, was rare in the normal Coloured population 
group studied (0/24, table 3-5) and was common in the White population studied (1/5, 
table 3-5). This is generally expected with a founder effect. The fact that a haplotype 
similar to the founder haplotype is seen in the White unaffected group analysed is an 
indication that the Q276X mutation is likely to have arisen within Europe before 
colonisation of South Africa in 1652.  
 
It is also interesting to note that there were very few haplotypes similar to LPh1 within 
the random Coloured individuals. This is surprising as the carrier rate for the Q276X 
mutation within this population is estimated at just over five percent (1/9 individuals are 
carriers), and hence the LPh1 haplotype that is associated with the Q276X mutation 
would be expected to be seen at a frequency of roughly five percent. Within the random 
Coloured population, only one haplotype similar to LPh1 was observed among the 81 
haplotypes estimated by Arlequin. Therefore, within this population, a haplotype similar 
to LPh1 was observed in just over one percent of the population. However, this 
discrepancy may be accounted for by the fact that a small sample size was used (n=48 
diploid individuals, of which only two were observed to be Q276X carriers, equalling just 
over four percent) and that the haplotypes were estimated by Arlequin and not observed 
haplotypes. In addition to this, while errors due to improper data capturing, incorrect 
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assigning of data and other forms of data biasing were avoided where possible, they 
cannot totally be excluded as a source of error. 
 
4.3 Linkage Disequilibrium in LP individuals 
As a founder effect was suspected with regards to LP in South Africa and this was 
supported by the presence of a single LP mutation associated with one founder haplotype, 
high levels of LD were expected between the markers used and the Q276X mutation 
itself. This was proven to be true, as significant LD was detected between all four 
microsatellite markers in both LP groups using the D’ statistic and highly significant LD 
was also detected between all four microsatellite markers and the Q276X mutation using 
the δ statistic in both LP groups.  
 
The high level of LD detected in this study was further accentuated by the fact that 
dinucleotide microsatellite markers were used to detect LD. Dinucleotide microsatellite 
markers are probably the fastest mutating class of markers within the genome, with 
mutation rates of 4.5 x 10-4 per allele transfer56 not uncommon. When using these 
markers to detect LD, it would be expected that detectable LD would decrease relatively 
rapidly as each marker mutated away from the original allele that was in LD. In contrast, 
when using single nucleotide polymorphisms (SNPs) much larger areas in LD could be 
detected, as SNPs generally have a very low mutation rate and LD detected with SNPs is 
likely to decay only due to recombination. LD detected by microsatellites is likely to 
decay due to recombination and mutation at each locus. A corollary of this is that SNPs 
are more sensitive at detecting LD, and that if LD is detected with microsatellites, the LD 
most probably will have originated relatively recently. Additionally, if LD is detected 
with microsatellite markers, if the same genomic segment is investigated with SNP 
markers, it is likely that LD will be detected over a larger genomic segment. 
 
It is not known when the mutational event that created the Q276X mutation occurred, but 
it has been shown that the Q276X mutation was introduced into South Africa around or 
very soon after 1652. Therefore the Q276X mutation has been in South Africa for 352 
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years or approximately 17 generations. This is a short genetic time, and therefore the 
original haplotype associated with the Q276X mutation has not had much time to decay 
into new haplotypes. This will lead to high amounts of LD seen within the LP patients of 
South Africa with respect to the markers used and the Q276X mutation. 
 
As expected, in the larger, less consanguineous White population, no significant LD 
could be detected in this study, while the smaller Coloured population of Namaqualand 
showed more significant LD. However, taking into account the population history of the 
Coloured population, the amount of LD seen was lower than expected. Perhaps this is an 
indication that the Namaqualand population is more genetically heterogeneous than was 
previously thought, that there is more immigration into this population than was 
previously thought, or that perhaps the general population of Namaqualand is becoming 
aware of the problem of LP in their community and are actively avoiding consanguineous 
relationships or seeking out partners whose families have no history of LP. Perhaps all 
the above suggestions are acting synergistically to increase the level of genetic 
heterogeneity seen in the Namaqualand population. 
 
4.4 Variation within the ECM1 gene 
In order to identify common ECM1 variants, a screening approach was taken and 
therefore ECM1 was screened using dHPLC for common variants by using a small 
sample size (20 individuals from three populations). Variants that were detected by 
dHPLC were then sequenced to determine the actual base change. 
 
dHPLC analysis in some cases is unable to differentiate between different variants within 
an amplimer.48 It is therefore essential to identify the underlying DNA mutation and to 
screen all individuals with variant dHPLC patterns with a more specific detection 
method. One method that is highly specific is restriction fragment length polymorphism 
(RFLP). RFLP uses a restriction endonuclease that cuts the amplimer at a specific DNA 
sequence. Mutations can abolish or create new restriction endonuclease recognition sites, 
hence a specific restriction endonuclease either will not cut or will cut that sequence, 
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respectively. Restriction endonucleases are specific enough that if a sequence differs by 
just one base from its recognition sequence, then it will not cut the DNA at that site. 
Therefore, if time were not a limiting factor, the variants identified in this study would 
have been specifically examined for variant frequencies. This would have been done in a 
larger sample set for each of the three populations investigated. 
 
Two variations of the dHPLC screening method were used in this study, namely the 
mixing and the non-mixing methods. The choice of moving away from the mixing 
method to the non-mixing method for identifying variants with dHPLC will be criticized 
by some, as this disallows the direct comparison between exons one to eight pI (analysed 
with the mixing method) and exons eight pII to ten (analysed with the non-mixing 
method). This is because the mixing method identifies more heteroduplex patterns than 
the non-mixing method will. However, the differences in frequencies identified will be 
small and are likely not to be significant. If one assumes that there is only one variant 
within a genomic segment being analysed by dHPLC and assuming the variation is in 
Hardy-Weinberg equilibrium, the mixing method will identify (2pq + q2)N variants 
(assuming q to be the frequency of the rarer allele and the reference homozygote is 
homozygous for the common allele or p2). Similarly, the non mixing method will identify 
only (2pq)N variants within a group of N individuals. Therefore, the difference in the 
number of heteroduplexes identified by the two methods will be q2N, which would be 
small as it is derived from the rarer allele. 
 
If we take the Q276X mutation within the random Namaqualand Coloured population 
sample as an example, which has been shown to be in Hardy-Weinburg equilibrium, the 
mixing method would theoretically identify (0.104 +  0.003) × 100 = 10.7 or 11 variants 
while the non-mixing method would theoretically identify (0.104) × 100 = 10.4 or 10 
variants. Practically, if the 100 random Namaqualand Coloured samples were used for 
dHPLC analysis to identify the Q276X mutation, 11 dHPLC heteroduplex patterns would 
have been identified using the non-mixing method while 11 dHPLC heteroduplex 
patterns would have been identified using the mixing method. This is because no Q276X 
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homozygotes were identified within the 100 random samples. Therefore, the frequencies 
obtained from the two methods are likely to be comparable.  
 
Should there be a second variant within the genomic segment analysed that creates a 
similar dHPLC heteroduplex pattern to the Q276X pattern, this will create a false 
frequency for the Q276X mutation. This however is a problem inherent to both the 
mixing and non-mixing methods, and therefore, based on the information given above, 
the two methods may tentatively be used interchangeably. However, as the rarer allele 
increases in frequency, the difference between the two methods becomes larger and 
hence the larger the error becomes. Table 4-1 estimates the differences that would be 
observed between the two methods for a range of q values. 
 
Table 4-1: Error calculation for the percentage of heteroduplexes detected using dHPLC analysis for 
a range of q values 
p 0.99 0.90 0.80 0.70 0.60 0.51 
q 0.01 0.10 0.20 0.30 0.40 0.49 
2pq 0.0198 0.18 0.32 0.42 0.48 0.4998 
q2 0.0001 0.01 0.04 0.09 0.16 0.2401 
Mixing 
Method (%) 1.99 19.00 36.00 51.00 64.00 73.99 
Non-Mixing 
Method (%) 1.98 18.00 32.00 42.00 48.00 49.98 
Difference 
(%) 0.01 1.00 4.00 9.00 16.00 24.01 
p and q are the frequencies of the common and rare allele respectively, while 2pq is the expected frequency 
of the heterozygote and q2 is the expected frequency of the rare homozygote. Mixing method is the 
percentage of heteroduplexes identified using the mixing method and similarly non-mixing is the 
percentage of heteroduplexes identified using the non-mixing method in a group of 100 individuals. 
Difference is the expected percentage of heteroduplexes missed by the non-mixing method in relation to the 
mixing method. 
 
If the frequency data obtained from dHPLC in this study are investigated for an 
underestimation in heteroduplex frequency, exons one through seven will have negligible 
underestimation of heteroduplex frequencies as they were analysed with the mixing 
method, while exons eight to ten should be investigated for underestimation due to the 
non-detection of homozygous rare alleles (q2). The average variation frequencies 
(averaged from all three populations, and rounded up to the nearest 0.1) for exons eight, 
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nine and ten are 0.20, 0.20 and 0.00, respectively. Therefore 2pq for exons eight, nine and 
ten are 0.20, 0.20 and 0.00, respectively. If data from Table 4-1 are used, we can expect 
that between one and four percent of heteroduplexes were missed for exons eight and 
nine, while no variants from exon ten were missed. 
 
All the exons of ECM1 were successfully screened by dHPLC in the 60 individuals. 
Sequencing results were obtained for only exons two, three, four five and the first part of 
exon six. Sequencing for variants in the other exons was not completed due to time 
constraints. All variants identified were either intronic or reflected synonymous variation, 
with the exception of the T130M missense mutation. Variation within ECM1 exon seven 
would have been especially interesting as it is the ECM1 isoform that contains exon 
seven (ECM1a) that plays the more important biological role. Variant frequencies were 
not investigated at the DNA level in all samples, again due to time constraints. 
 
The T130M mutation is a missense mutation that changes a threonine amino acid to a 
methionine. This variation is seen in the fourth exon and is therefore in the cysteine free 
domain of ECM1. It is therefore theoretically unlikely to alter the ligand binding 
properties of ECM1. While the T130M substitution changes a polar hydrophillic amino 
acid to a non-polar hydrophobic amino acid, this is not likely to alter the properties of 
ECM1 significantly. This is thought because the T130M substitution has been identified 
in at least three different studies, namely this study, Hamada et al.’s study,3 and the 
T130M substitution is a known variant in the SNPper database (http://snpper.chip.org). 
Using the BsmI restriction endonuclease, Hamada et al. found that the T130M variation 
was polymorphic, with the T allele having a frequency of 0.61 and the M allele having a 
frequency of 0.39 in a group of 36 individuals from mixed ethnic backgrounds. 
 
Notably, the majority of the variants identified in this study (6/8) are cytosine (C) to 
thiamine (T) transitions or the complimentary version of C→T transitions, namely 
guanine (G) to adenine (A) transitions. Incidentally, the Q276X mutation results from a 
C→T transition. Additionally, of the base changes causing pathogenic mutations for LP, 
nine of the eleven are due to C→T or G→A transitions. (I. Chan, personal 
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communication, Table 4-2). Table 4-2 summarises all known variation within the ECM1 
gene. Of the 30 base substitutions in Table 4-2, 21 (70%) are due to C→T transitions 
(this includes G to A transitions). The most common mechanism of inducing a C to T 
transition occurs when the C (especially the C of CpG dinucleotides) is methylated and 
subsequently deaminated to a T.49 Methylation is a common form of gene regulation and 
is associated specifically with the down regulation of transcription.57 This may suggest 
that ECM1 is under tight transcriptional control via methylation. 
 
 
Table 4-2: Summary of all known variation within the ECM1 gene (as of 12/2004) 
SNPper SNP rs 
number 
Relative position 
and nucleotide 
change 
Amino acid 
change Description 
rs1050867 nt 39 C→G n/a SNPper 
rs4995236 nt 1122 G→T n/a SNPper 
n/a nt 1314 C→T n/a TS 
n/a nt 1400 C→T n/a TS 
n/a nt 1448 C→T Q32X IC 
n/a nt 1486 G→A n/a TS 
n/a nt 1590 C→T R53X IC 
n/a nt 1673 A→G n/a TS 
n/a nt 1732 del G n/a IC 
n/a nt 1823 C→T P77P TS 
n/a nt 1875 C→T Q95X IC 
n/a nt 2031 C→T Q114X IC 
n/a nt 2057 C→T H122H TS 
n/a nt 2655 C→A n/a TS 
rs3737240 nt 2773 C→T T130M SNPper, WvH-T, H 
n/a nt 2782 ins C n/a IC 
n/a nt 2788 del T n/a IC 
n/a nt 2822 del 3 ins 16 n/a IC 
n/a nt 2823 ins AA n/a IC 
n/a nt 2864 G→A W160X IC 
rs1050874 nt 2876 C→G L164L SNPper 
n/a nt 2883 T→A F167L IC 
n/a nt 2883 T→C F167I IC 
rs4970979 nt 3258 C→T n/a SNPper 
n/a nt 3274 del TG n/a IC 
n/a nt 3324 del A n/a IC 
n/a nt 3369 C→T R243X IC 
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n/a nt 3431 del C n/a IC 
n/a nt 3468 C→T Q276X IC 
n/a nt 3558 del A n/a IC 
n/a nt 3678 C→T Q346X IC 
n/a nt 3719 G→A W359X IC 
rs875514 nt 3973 C→G n/a SNPper 
n/a nt 4249 ins C n/a IC 
n/a nt 4312 del C n/a IC 
rs13294 nt 4405 A→G G415S SNPper, H 
rs945715 nt 4949 C→T n/a SNPper 
n/a nt 5067 del A n/a IC 
rs1050901 nt 5320 A→G G528R SNPper 
rs1050904 nt 5342 C→T S535F SNPper 
rs3209760 nt 5361 A→G X541W SNPper 
rs1050911 nt 5418 C→T n/a SNPper 
n/a Exon 9 – 10 del n/a IC 
TS indicates variation identified during this study, IC indicates LP causing mutations (I. Chan personal 
communication), H indicates SNPs identified by Hamada et al.3 and SNPper indicates known variation 
taken from the CHIP Bioinformatics Tools website using the SNPper database (http://snpper.chip.org). The 
relative position is measured from the first nucleotide of the 5’ untranslated region (UTR) to the last 
nucleotide of the 3’ UTR. 
 
4.5 Future studies on LP and ECM1 
The gene that is mutated in LP, ECM1, has now not only been identified, but 
investigation into the properties of ECM1 has now begun. Investigation of the ECM1 
gene in the South African population has progressed with regards to mutation types, 
mutation frequency and normal variation found within it. A large genomic segment 
around ECM1 (9.98Mb) has been investigated and found to be in significant LD with the 
Q276X mutation and with each marker in South African LP individuals. Therefore future 
studies with regard to LP could now be aimed at association studies with common skin 
scarring disorders and cancer, with treatment development and defining the physiological 
dynamics of ECM1 in normal and abnormal systems. An example of where this has 
already occurred is with lichen sclerosis, which exhibits some clinical similarity to LP.58 
Oyama et al.58 have reported that lichen sclerosis patients have autoantibodies against 
ECM1. Oyama et al. suggest that this perturbation of ECM1 function is likely to explain 
some of the clinical symptoms that are similar in LP and lichen sclerosis. 
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4.5.1 Genetic studies 
As there is now evidence that partial rescue of the LP phenotype is possible due to 
aberrant splicing out of the exon with the mutation,3 ECM1 splicing should be 
investigated in more depth and variation that is near or within ECM1 should be 
investigated for effects on splicing. The fact that the human body has a mechanism 
whereby it recognises the lack of a certain protein (ECM1 in this case) and attempts to 
bypass the mutated exon with blind splicing out of exons, has interesting implications for 
the evolution of the human genome and genomes in general. If a mutation that induces 
skipping of certain exons is more beneficial to the individual and induces a positive 
selective advantage in the individual affected, then that variant and hence the skipping of 
the exon would be favoured and over time the variant and exon skipping may become 
fixed in the population. This may already have happened to ECM1 exon 5a, as expression 
of this exon has only been detected in cancer cells. However, it may be that exon 5a is 
only needed on rare occasions in humans, and for the majority of the cases it is spliced 
out during mRNA processing. 
 
As there is a remarkable amount of variability in the severity of LP symptoms seen in the 
Namaqualand LP population (J. McGrath, personal communication) and taking into 
account that all Namaqualand LP individuals are genotypically identical for the Q276X 
mutation, the genotype-phenotype discrepancy suggests that there are likely to be other 
modifiers, both genetic and environmental, that can reduce or enhance the pathogenic 
effect of the Q276X mutation in the homozygous state. Therefore, on the genetic side, the 
genes whose proteins interact with ECM1 or which play a role in the same physiological 
processes as ECM1 should be investigated for variation. Once identified, association 
studies may then be conducted to determine if the variants are responsible for the lack of 
genotype-phenotype correlation in LP patients.  
 
Additionally, as lack of ECM1 is now implicated in at least two skin disorders (LP and 
lichen sclerosis), it is likely that functional variants within ECM1 will have an impact on 
normal skin. For example, variant A in ECM1 may predispose a person to excessive scar 
formation while variant B may delay proper skin healing.  
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The strong LD seen within the Coloured and White LP groups observed with 
dinucleotide microsatellite markers suggest that there may be a much larger genomic 
segment that would show LD if SNP markers were used to detect LD. Many other studies 
have shown that there are other founder effects within the South African White 
population, a few examples include porphyria varigata (PV)23, familial 
hypercholesterolaemia (FH)24 and pseudoxanthoma elasticum (PXE).26 As these 
disorders have reached relatively high frequencies because of founder effects in South 
Africa, the genomic areas around the genes responsible for PV, FH and PXE are likely to 
show high LD with markers in those regions. If this is extrapolated, it is likely that many 
other locus pairs, which may or may not be associated with genetic disorders, will show 
significant LD in the White population of South Africa. In contrast, the Coloured 
populations of South Africa have not been as extensively investigated as the White 
population have been. The Coloured populations would be of great interest, as they are 
hybrid populations derived from the admixture of the White population and the Black, 
Khoisan or other populations found in South Africa.39 Therefore the Coloured 
populations of South Africa would each be expected to show high amounts of LD at 
many locus pairs, some of which would be similar to the White population. Therefore it 
would be interesting to investigate the Coloured populations of South Africa for LD and 
then to compare and contrast the findings from the Coloured populations to the findings 
of the South African White population.  
 
The White population of South Africa is larger than the many small Coloured populations 
and therefore would be expected to show less LD, even though the majority of the White 
population of South Africa arose from relatively few individuals. This is borne out by the 
observation that this study has found the Namaqualand Coloured group to have more 
markers in significant LD in than the White group. Extrapolating from this, the Coloured 
populations of South Africa may be more likely to demonstrate LD and may make 
excellent target populations on which to conduct association studies for polygenic and 
multifactorial disorders. 
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4.5.2 Protein studies 
Future studies on LP and hence ECM1 clearly need to be aimed at elucidating the exact 
mode of action of the mutated ECM1 protein or how exactly normal biology is perturbed 
by the absence of ECM1. In order to do this, proteins that the normal ECM1 protein 
interacts with in vivo need to be identified and then these proteins need to be fully 
characterized with regards to their physiological functions. Further to this, the calcium 
binding domains of ECM1 need to be properly investigated and their effect on or 
interactions with other proteins elucidated. A hypothetical physiological pathway could 
then be compiled, which could be used to identify drug targets. This could be used not 
only for treatment of LP, but in all dermatological functions that ECM1 is involved in. 
 
4.5.3 New treatments for LP 
A novel idea for treatment of LP patients is to substitute the ECM1a protein in the 
affected organs. A method of accomplishing this would be to genetically modify bacteria 
to produce ECM1a. The resultant ECM1a protein could possibly be used as a treatment 
for LP, and may be administered to a patient as a topical cream, as the majority of the 
clinical symptoms are dermatological in nature. This would be viable only if the skin is 
permeable to a protein of ECM1’s size and provided it is capable of localising correctly 
within the extracellular matrix. An aerosolised form of ECM1a may be of benefit in the 
reduction of the infiltration of the vocal cords, leading to a reduction in hoarseness. As 
the hyaline deposits do not grow significantly over time, there may be a form of “hyaline 
homeostasis” whereby excess hyaline material is removed from the affected organs while 
more is deposited. Therefore, if the cause of the hyaline deposition is removed, the 
“hyaline homeostasis” mechanism may remove the residual hyaline material, perhaps 
returning the affected area back to normal. Other symptoms, such as the calcification of 
the temporal lobes could not be treated in this manner. Systemic gene therapy would be 
more applicable in this situation, provided the addition of ECM1 protein was able to 
reverse the calcification process. Naturally, these therapies would have to undergo 
extensive testing in order to investigate the proof of concept and to evaluate the 
effectiveness of such a treatment before implementation.  
 73 
4.6 Implications of this study 
The test for the Q276X mutation is a simple restriction digestion of a PCR product that 
now can be used as part of a routine diagnostic service in any molecular genetics 
laboratory. The RFLP test using the BfaI restriction endonuclease can simply and easily 
differentiate between a Q276X homozygote, heterozygote and a non-Q276X 
homozygote. Therefore it is now possible to rapidly confirm a clinical diagnosis of LP at 
the molecular level, thereby allowing the patient to understand the genetic basis of their 
disorder. He/she can now make more informed choices with regards to their health and 
importantly, he/she can make informed reproductive choices.  
 
Additionally, the BfaI RFLP test now allows for carrier screening, especially in at-risk 
populations. This study has shown that of the 36 South African LP patients, all were 
homozygous for the Q276X mutation. Therefore, if a South African individual is negative 
for the Q276X mutation after a BfaI RFLP test, then we can be relatively confident that 
this person is not likely to suffer from LP nor be a carrier of an LP mutation. This study 
cannot exclude the possibility that there may be another, rare, LP mutation at a very low 
frequency in the South African population nor can it exclude the possibility of a de novo 
LP mutation occurring within an individual. In these scenarios, a proper clinical diagnosis 
is essential, and then molecular screening of the individual’s ECM1 gene to find the 
mutation could commence, if there is a strong suspicion of an LP diagnosis. 
 
If the BfaI RFLP test was not available for whatever reason, linked marker analyses using 
the ND1, D1S2343, D1S305 and D1S2624 markers could be performed. However, these 
markers span 9.98Mb, and hence the chance of recombination is roughly 10% per 
meiosis in the genomic region covered by these markers.49 Therefore, the marker 
D1S2343 should be given preference when diagnosing LP in an individual, as it is the 
marker that is situated the closest to the ECM1 gene, followed by D1S305, ND1 and 
lastly D1S2624. Therefore, preference should be given in that order when testing for LP 
in a family where the Q276X mutation status is unknown. The alleles that are associated 
with the Q276X mutation are 12 (D1S2343), 23 (D1S305), 19 (ND1) and 22 (D1S2624). 
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If there is a combination of two or more of these alleles, then further investigation is 
warranted, and the BfaI RFLP test is highly recommended. 
 
With regards to a couple who are both known to be Q276X carriers and are therefore at 
one in four risk of conceiving a child affected with LP, pre-natal screening can now be 
offered as an option. If the foetus were diagnosed with LP at the molecular level, the 
couple would have the option of aborting the affected foetus, should they so wish. This 
option has not yet been explored in the Namaqualand population, and since LP is rarely 
life threatening, it is uncertain whether a prenatal test would ever be requested.  This 
study has established carrier rates of the Q276X mutation for the populations affected in 
South Africa. This gives a genetic counsellor and hence the patient more accurate 
information regarding the chances of being an LP carrier, or the chances of any couple 
taken at random from the South African White or Namaqualand Coloured population of 
conceiving a child affected with LP. 
 
In summary, the LP population of South Africa, especially the Coloured population of 
Namaqualand, has made a large contribution to the understanding of LP. The South 
African LP community is likely to carry on contributing to the understanding of LP by 
making themselves available and amenable to novel treatments for LP. The medical and 
scientific community of South Africa should seize this opportunity to understand the 
molecular pathogenic aetiology of LP in greater detail. If they do, and are able to 
conceive of and create a treatment for LP, this will result in the lessening of the burden of 
disease in people who are in need. 
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CHAPTER 5 Appendices 
5.1 Salting-out protocol for extracting DNA from whole blood 
Collect blood in ACD or EDTA tubes. 
Centrifuge sample and remove plasma, left with red blood cells and white blood cells. 
Transfer to Nunc tube. 
Fill each tube to the 45/50ml mark with cold Sucrose-Triton X Lysing buffer. 
Invert the tube to mix. 
Centrifuge for 10 minutes at 4oC (2300rpm). 
Pour off supernatant fluid. 
Wash in 20-25ml Sucrose-Triton X Lysing Buffer. 
Put on ice for 5 minutes. 
Centrifuge for 5 minutes at 4oC (2300rpm). 
Pour off the supernatant fluid. 
Add 3ml T20E5. 
Add 200µl 10% SDS. 
Add 500µl Proteinase K Solution. 
Mix well by inversion. 
Put at 42oC to 50oC overnight (no need to agitate). 
Add 1ml saturated NaCl. 
Mix well by inversion. 
Put on ice for 5 min. 
Centrifuge for 30 minutes at 2500rpm. 
A white pellet should be visible which contains proteins that have been precipitated by 
the salt. If no pellet is visible, centrifuge again. If still no pellet is visible, add another 
1ml saturated NaCl. 
Transfer the supernatant containing the DNA to a new tube. 
Add two volumes of absolute ethanol and keep at room temperature. 
Agitate gently and spool, fish or precipitate DNA. If precipitating, do not spin too long to 
avoid salts and proteins precipitating as well. 
Wash DNA in 70% ice cold ethanol. 
Air-dry DNA. 
Dissolve DNA in appropriate volume (±300µl) of TE buffer or ddH2O. 
 
5.2 NucleoSpin Extract protocol for direct purification of PCR products 
Adjust PCR sample volume to 50µl with TE buffer (pH 7.5) if the PCR sample volume is 
less than 50µL. 
Mix four volumes of buffer NT2 with one volume of PCR sample. 
Insert the NucleoSpin Extract column into a 2ml collecting tube.  
Load sample onto the column and centrifuge for 1 minute at 11000 x g.  
Discard the flow-through and place the NucleoSpin Extract column back into the 2ml 
collecting tube. 
Add 600µl buffer NT3. 
Centrifuge for 1 minute at 11000 x g. 
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Discard the flow-through and place the NucleoSpin Extract column back into the 2ml 
collecting tube. 
Add 200µl buffer NT3. 
Centrifuge for 2 minutes at 11000 x g. 
Incubate the NucleoSpin Extract columns for 2 – 5 minutes at 70oC. 
Place the NucleoSpin Extract column into a clean 1.5ml microcentrifuge tube. 
Add 25 – 50µl elution buffer NE. 
Incubate the NucleoSpin Extract columns for 1 minute at room temperature. 
Centrifuge for 1 minute at 11000 x g. 
 
The elute contains the purified PCR product and is ready to be used as template for 
subsequent sequencing reactions. 
  
5.3 SigmaSpin Post-Reaction Purification Protocol for purification of cycle 
sequencing products 
Loosen the column cap by half a turn and snap off the bottom closure. 
Place the column into a collection tube and centrifuge at 750 x g for 2 minutes. 
Discard the elute and the collection tube. 
Place the column into a new microcentrifuge tube. 
Pipette the cycle sequencing reaction directly into the center of the column. 
Centrifuge the above assembly for 4 minutes at 750 x g. 
Discard the column but retain the elute. 
 
The eluted contains the purified cycle sequencing product in water containing 
approximately 25ppm preservative. 
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5.4 Microsatellite marker results 
 
Table 5-1: Microsatellite results for the random Coloured individuals (N = 60, LP 1 - LP 50), 
Coloured LP patients and their family members (N = 157, LP 101 - LP 157), White LP patients and 
their family members (N = 12, LP 502 - LP 513) and the random White individuals (N = 30, RW 251 
– 280).  
Marker Nov Di 1 D1S2343 D1S305 D1S2624 
Code Alleles Alleles Alleles Alleles 
17 12 19 24 LP 1 
20 16 25 24 
20 NR NR NR LP 2 
24 NR NR NR 
15 19 19 21 LP 3 
17 26 26 21 
17 21 19 20 LP 4 
17 21 21 22 
NR 23 NR NR LP 5 
NR 23 NR NR 
19 NR NR NR LP 6 
21 NR NR NR 
18 NR 20 NR LP 7 
18 NR 26 NR 
21 22 20 20 LP 8 
21 22 26 22 
19 20 24 20 LP 9 
22 20 27 21 
16 12 21 20 LP 10 
20 20 24 22 
17 12 19 18 LP 11 
17 19 23 18 
17 12 23 20 LP 12 
19 22 25 22 
17 12 19 18 LP 13 
23 19 23 19 
17 19 20 19 LP 14 
17 19 32 21 
20 12 19 20 LP 15 
21 19 21 22 
17 18 23 NR LP 16 
17 19 26 NR 
17 12 23 16 LP 17 
19 17 23 16 
15 16 21 19 LP 18 
15 23 24 22 
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18 17 19 15 LP 19 
20 18 27 18 
18 17 22 19 LP 20 
20 20 23 21 
15 19 19 18 LP 21 
18 21 21 20 
16 18 23 19 LP 22 
19 19 27 21 
18 18 19 19 LP 23 
19 19 25 20 
17 18 19 20 LP 24 
18 20 24 21 
15 19 19 20 LP 25 
17 26 26 22 
18 17 24 13 LP 26 
18 22 25 22 
21 18 19 16 LP 27 
21 20 21 19 
18 18 21 20 LP 28 
23 23 23 20 
17 18 19 18 LP 29 
20 22 20 21 
17 19 18 18 LP 30 
19 22 21 17 
20 17 27 17 LP 31 
20 18 27 19 
19 18 19 16 LP 32 
20 22 27 19 
17 19 20 19 LP 33 
21 22 23 21 
17 22 23 13 LP 34 
18 17 23 20 
17 18 24 19 LP 35 
18 21 26 22 
17 18 19 19 LP 36 
18 20 25 21 
15 21 19 16 LP 37 
17 24 27 18 
18 18 23 18 LP 38 
18 18 23 21 
18 18 18 19 LP 39 
21 20 23 19 
17 18 18 20 LP 40 
17 19 23 22 
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17 18 18 19 LP 41 
21 19 25 22 
17 12 21 18 LP 42 
20 12 23 22 
18 18 21 20 LP 43 
23 19 23 21 
18 12 21 19 LP 44 
20 22 26 19 
17 17 18 16 LP 45 
18 18 21 18 
17 12 23 22 LP 46 
19 19 23 23 
15 20 23 12 LP 47 
15 22 26 16 
19 17 23 18 LP 48 
21 19 28 20 
17 18 18 19 LP 49 
21 22 25 21 
17 12 18 17 LP 50 
17 20 19 20 
17 17 23 19 LP 51 
20 20 26 23 
20 18 24 19 LP 52 
21 21 26 19 
17 20 18 21 LP 53 
24 17 22 21 
20 NR NR NR LP 54 
24 NR NR NR 
NR NR NR 21 LP 55 
NR NR NR 21 
NR NR NR NR LP 56 
NR NR NR NR 
NR NR NR 18 LP 57 
NR NR NR 18 
NR NR NR 17 LP 58 
NR NR NR 17 
NR NR NR 18 LP 59 
NR NR NR 21 
NR NR NR 21 LP 60 
NR NR NR 21 
19 12 23 20 LP 101 
19 12 23 22 
19 12 23 20 LP 102 
17 20 24 22 
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19 12 23 23 LP 103 
19 12 26 23 
18 12 19 20 LP 104 
19 22 26 23 
16 12 19 19 LP 105 
19 17 23 22 
19 12 23 22 LP 106 
19 12 23 22 
19 12 18 22 LP 107 
19 12 23 22 
14 12 23 22 LP 108 
19 12 23 22 
14 12 18 19 LP 109 
17 19 23 22 
19 12 23 22 LP 110 
19 12 23 22 
19 12 23 20 LP 111 
19 12 23 22 
18 12 23 20 LP 112 
19 20 23 22 
19 12 23 22 LP 113 
19 12 23 23 
17 12 23 18 LP 114 
19 12 24 22 
19 12 23 22 LP 115 
19 12 23 22 
17 12 19 22 LP 116 
19 20 23 22 
17 12 22 18 LP 117 
19 12 23 22 
19 12 23 18 LP 118 
19 12 23 22 
17 12 23 22 LP 119 
19 18 23 23 
17 12 23 18 LP 120 
19 17 23 22 
19 12 23 22 LP 121 
19 12 23 22 
19 12 23 20 LP 122 
19 20 23 22 
19 12 23 22 LP 123 
19 12 23 22 
19 12 23 22 LP 124 
19 12 23 23 
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17 12 18 22 LP 125 
19 21 23 21 
19 12 18 21 LP 126 
21 19 23 23 
17 19 18 21 LP 127 
21 21 18 21 
19 12 19 22 LP 128 
19 12 23 23 
18 12 19 22 LP 129 
19 22 23 23 
19 12 23 18 LP 130 
23 19 23 22 
18 12 19 22 LP 131 
19 22 23 23 
17 12 23 22 LP 132 
19 18 23 22 
19 12 23 22 LP 133 
19 12 23 22 
19 12 20 19 LP 134 
20 18 23 22 
18 12 23 20 LP 135 
19 18 26 22 
19 12 23 22 LP 136 
19 12 23 22 
19 12 18 22 LP 137 
19 12 23 22 
19 12 18 22 LP 138 
21 18 27 20 
19 12 18 22 LP 139 
19 12 23 22 
19 12 18 22 LP 140 
19 12 23 22 
19 12 23 22 LP 141 
19 12 23 22 
19 12 23 22 LP 142 
19 12 23 22 
17 12 23 20 LP 143 
19 20 23 22 
19 12 23 22 LP 144 
19 12 23 22 
19 12 23 22 LP 145 
19 12 23 22 
19 12 23 22 LP 146 
19 12 23 22 
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19 12 23 22 LP 147 
19 12 23 22 
18 12 23 22 LP 148 
19 26 26 23 
19 12 23 22 LP 149 
19 12 23 22 
17 12 19 18 LP 150 
18 18 23 20 
17 12 19 20 LP 151 
19 12 23 22 
17 12 19 20 LP 152 
19 12 23 22 
19 12 23 22 LP 153 
19 12 23 23 
19 12 23 22 LP 154 
19 12 23 23 
17 12 21 20 LP 155 
19 12 23 22 
15 21 19 19 LP 156 
18 26 26 23 
19 12 23 22 LP 157 
19 12 23 23 
15 12 23 20 LP 502 
19 12 23 22 
19 12 23 22 LP 503 
19 12 23 22 
19 12 23 22 LP 504 
19 12 23 22 
19 12 23 22 LP 505 
19 12 23 22 
17 12 23 22 LP 506 
19 12 22 22 
15 12 23 20 LP 507 
19 12 23 19 
19 12 21 18 LP 508 
21 19 23 22 
17 12 18 18 LP 509 
19 19 23 22 
17 12 21 18 LP 510 
19 19 23 22 
17 12 23 18 LP 511 
19 12 23 22 
19 12 23 18 LP 512 
22 12 23 22 
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19 12 23 18 LP 513 
22 12 23 18 
18 12 18 18 RW 251 
18 12 19 20 
17 12 18 19 RW 252 
22 20 23 19 
16 12 18 20 RW 253 
17 19 21 22 
17 19 19 18 RW 254 
20 20 23 20 
17 12 21 20 RW 255 
22 17 23 22 
18 19 18 16 RW 256 
23 24 23 16 
17 12 18 19 RW 257 
22 21 19 20 
17 19 23 18 RW 258 
22 19 23 20 
18 20 18 20 RW 259 
18 21 19 22 
23 20 21 20 RW 260 
23 25 26 20 
16 19 18 18 RW 261 
17 20 24 21 
17 12 19 18 RW 262 
17 19 21 22 
17 12 18 18 RW 263 
21 19 19 21 
17 20 18 19 RW 264 
18 22 23 19 
17 12 18 16 RW 265 
20 19 23 18 
15 17 18 18 RW 266 
17 19 22 20 
18 18 23 17 RW 267 
18 19 23 19 
17 12 21 16 RW 268 
17 19 24 16 
18 19 18 16 RW 269 
22 20 21 18 
15 19 21 19 RW 270 
18 19 23 19 
20 12 18 19 RW 271 
22 19 23 21 
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17 12 21 20 RW 272 
22 20 23 22 
17 12 18 20 RW 273 
17 21 19 22 
15 21 19 16 RW 274 
18 23 21 16 
18 12 18 20 RW 275 
18 20 21 22 
17 19 18 18 RW 276 
18 21 21 20 
18 19 22 16 RW 277 
21 19 25 18 
15 12 19 18 RW 278 
17 19 21 20 
17 17 18 19 RW 279 
17 19 23 20 
17 12 19 20 RW 280 
17 19 21 22 
NR indicates no result 
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5.5 LP pedigrees 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
The above eight individuals were not part of a pedigree as they are isolated cases from 
independent families.  
 
 
The alleles for all individuals, except for LP 501 (where gametic phase cannot be 
determined), are shown as haplotypes. 
 
 
 
Key: 
 
 
 
 
 
LP 149   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 157   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 23 
LP 144   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 504   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 110   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 107   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 18 23 
D1S2624 22 22 
LP 501   
Marker Allele 1 
Allele 
2 
Nov Di1 17 20 
Q276X N N 
D1S2343 17 21 
D1S305 19 21 
D1S2624 19 19 
LP 503   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
Unaffected male and female, 
respectively 
 
LP male and female, respectively 
 
 
LP carrier male and female, 
respectively 
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Red in this pedigree indicates non-mendelian inheritance, and is likely to be caused by 
non-paternity. 
 
 
 
 
 
LP 148   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 26 
D1S305 23 26 
D1S2624 22 23 
LP 155   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 21 
D1S2624 22 20 
LP 147   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 156   
Marker Allele 1 
Allele 
2 
Nov Di1 15 18 
Q276X N N 
D1S2343 21 26 
D1S305 19 26 
D1S2624 19 23 
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LP 153   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 23 
LP 154   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 23 
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LP 150   
Marker Allele 1 
Allele 
2 
Nov Di1 17 18 
Q276X N N 
D1S2343 12 18 
D1S305 19 23 
D1S2624 20 18 
LP 138   
Marker Allele 1 
Allele 
2 
Nov Di1 19 21 
Q276X Y N 
D1S2343 12 18 
D1S305 18 27 
D1S2624 22 20 
LP 151   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 19 
D1S2624 22 20 
LP 152   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 19 
D1S2624 22 20 
LP 140   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 18 23 
D1S2624 22 22 
LP 139   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 18 23 
D1S2624 22 22 
LP 137   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 18 23 
D1S2624 22 22 
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LP 148   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 26 
D1S305 23 26 
D1S2624 22 23 
LP 147   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 146   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 145   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 143   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 20 
D1S305 23 23 
D1S2624 22 20 
LP 141   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 142   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 116   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 20 
D1S305 23 19 
D1S2624 22 22 
LP 117   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 175 
D1S2624 22 18 
LP 115   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 136   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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Blue in this pedigree indicates ambiguity of haplotypes with regards to D1S305 and 
D1S2624 in LP 128 and LP 131. This can be accounted for if there was a 
recombinational event during gametogenesis in LP 129. 
 
 
 
 
 
 
 
 
 
 
LP 129   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 22 
D1S305 23 19 
D1S2624 22 23 
LP 130   
Marker Allele 1 
Allele 
2 
Nov Di1 19 23 
Q276X Y N 
D1S2343 12 19 
D1S305 23 23 
D1S2624 22 18 
LP 128   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 19 
D1S2624 22 23 
LP 131   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 22 
D1S305 23 19 
D1S2624 22 23 
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LP 134   
Marker Allele 1 
Allele 
2 
Nov Di1 19 20 
Q276X Y N 
D1S2343 12 18 
D1S305 23 20 
D1S2624 22 19 
LP 135   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 18 
D1S305 23 26 
D1S2624 22 20 
LP 133   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 114   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 24 
D1S2624 22 18 
LP 113   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 23 
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Blue in this pedigree indicates that phase cannot be determined for marker D1S2624 in 
LP 111, as both his alleles at D1S2624 are identical to his mothers and hence it is not 
clear which allele he has inherited from his mother. 
 
 
 
 
 
 
 
 
 
 
 
LP 112   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 20 
D1S305 23 23 
D1S2624 20 22 
LP 111   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 20 22 
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LP 132   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 18 
D1S305 23 23 
D1S2624 22 22 
LP 102   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 20 
D1S305 23 24 
D1S2624 20 22 
LP 101   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 20 22 
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LP 126   
Marker Allele 1 
Allele 
2 
Nov Di1 19 21 
Q276X Y N 
D1S2343 12 19 
D1S305 23 18 
D1S2624 23 21 
LP 125   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 21 
D1S305 23 18 
D1S2624 22 21 
LP 124   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 23 22 
LP 127   
Marker Allele 1 
Allele 
2 
Nov Di1 21 17 
Q276X N N 
D1S2343 19 21 
D1S305 18 18 
D1S2624 21 21 
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LP 105   
Marker Allele 1 
Allele 
2 
Nov Di1 19 16 
Q276X Y N 
D1S2343 12 17 
D1S305 23 19 
D1S2624 22 19 
LP 106   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 104   
Marker Allele 1 
Allele 
2 
Nov Di1 19 18 
Q276X Y N 
D1S2343 12 22 
D1S305 26 19 
D1S2624 23 20 
LP 103   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 26 
D1S2624 23 23 
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LP 120   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 17 
D1S305 23 23 
D1S2624 22 18 
LP 122   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y N 
D1S2343 12 20 
D1S305 23 23 
D1S2624 22 20 
LP 123   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
LP 121   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 119   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 18 
D1S305 23 23 
D1S2624 22 23 
LP 118   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 18 
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LP 506   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 12 
D1S305 23 22 
D1S2624 22 22 
LP 505   
Marker Allele 1 
Allele 
2 
Nov Di1 19 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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LP 507   
Marker Allele 1 
Allele 
2 
Nov Di1 15 19 
Q276X Y N 
D1S2343 12 12 
D1S305 23 23 
D1S2624 20 19 
LP 508   
Marker Allele 1 
Allele 
2 
Nov Di1 19 21 
Q276X Y N 
D1S2343 12 19 
D1S305 23 21 
D1S2624 18 22 
LP 502   
Marker Allele 1 
Allele 
2 
Nov Di1 19 15 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 18 20 
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LP 109   
Marker Allele 1 
Allele 
2 
Nov Di1 14 17 
Q276X Y N 
D1S2343 12 19 
D1S305 23 18 
D1S2624 22 19 
LP 108   
Marker Allele 1 
Allele 
2 
Nov Di1 14 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 22 22 
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Blue in this pedigree indicates that phase could not be determined for markers Nov Di1 
and D1S2624, as LP 509, LP 510 and LP 511 all share identical alleles at these two loci. 
 
 
 
 
 
 
 
 
 
 
 
 
LP 509   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 19 
D1S305 23 18 
D1S2624 22 18 
LP 510   
Marker Allele 1 
Allele 
2 
Nov Di1 19 17 
Q276X Y N 
D1S2343 12 19 
D1S305 23 21 
D1S2624 22 18 
LP 511   
Marker Allele 1 
Allele 
2 
Nov Di1 17 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 18 22 
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Red in this pedigree indicates a discrepancy at marker D1S2624 in a sib pair that is 
homozygous for the Q276X mutation. The alleles at the D1S2624 locus would be 
expected to be similar. Possible reasons for the discrepancy are mutation, recombination 
or lab error. 
 
 
 
 
 
LP 513   
Marker Allele 1 
Allele 
2 
Nov Di1 22 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 18 18 
LP 512   
Marker Allele 1 
Allele 
2 
Nov Di1 22 19 
Q276X Y Y 
D1S2343 12 12 
D1S305 23 23 
D1S2624 20 22 
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5.6 Arlequin sample files 
5.6.1 Random Namaqualand population genotypic LD estimation and haplotype 
estimation project file 
[Profile]  
 
Title="Random Namaqualand Population Haplotype Estimation"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 1 
     LocusSeparator= WHITESPACE 
     GameticPhase= 0 
     RecessiveData= 0 
     RecessiveAllele= null 
     MissingData= '?' 
# Some advenced settings the experienced user can unkomment 
#     Frequency= ABS             # - {ABS, REL}  
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
 
[Data]  
 
[[Samples]]  
 
 SampleName="Random Namaqualand Population"  
 SampleSize= 48 
 SampleData= {   
 #Sample of genotypic data (4 loci): 
 LP1 1 17 12 19 24 
   20 16 25 24 
 LP3 1 15 19 19 21 
   17 26 26 21 
 LP4 1 17 21 19 20 
   17 21 21 22 
 LP8 1 21 22 20 20 
   21 22 26 22 
 LP9 1 19 20 24 20 
   22 20 27 21 
 LP10 1 16 12 21 20 
   20 20 24 22 
 LP11 1 17 12 19 18 
   17 19 23 18 
 LP12 1 17 12 23 20 
   19 22 25 22 
 LP13 1 17 12 19 18 
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   23 19 23 19 
 LP14 1 17 19 20 19 
   17 19 32 21 
 LP15 1 20 12 19 20 
   21 19 21 22 
 LP17 1 17 12 23 16 
   19 17 23 16 
 LP18 1 15 16 21 19 
   15 23 24 22 
 LP19 1 18 17 19 15 
   20 18 27 18 
 LP20 1 18 17 22 19 
   20 20 23 21 
 LP21 1 15 19 19 18 
   18 21 21 20 
 LP22 1 16 18 23 19 
   19 19 27 21 
 LP23 1 18 18 19 19 
   19 19 25 20 
 LP24 1 17 18 19 20 
   18 20 24 21 
 LP25 1 15 19 19 20 
   17 26 26 22 
 LP26 1 18 17 24 13 
   18 22 25 22 
 LP27 1 21 18 19 16 
   21 20 21 19 
 LP28 1 18 18 21 20 
   23 23 23 20 
 LP29 1 17 18 19 18 
   20 22 20 21 
 LP30 1 17 19 18 18 
   19 22 21 17 
 LP31 1 20 17 27 17 
   20 18 27 19 
 LP32 1 19 18 19 16 
   20 22 27 19 
 LP33 1 17 19 20 19 
   21 22 23 21 
 LP34 1 17 22 23 13 
   18 17 23 20 
 LP35 1 17 18 24 19 
   18 21 26 22 
 LP36 1 17 18 19 19 
   18 20 25 21 
 LP37 1 15 21 19 16 
 110 
   17 24 27 18 
 LP38 1 18 18 23 18 
   18 18 23 21 
 LP39 1 18 18 18 19 
   21 20 23 19 
 LP40 1 17 18 18 20 
   17 19 23 22 
 LP41 1 17 18 18 19 
   21 19 25 22 
 LP42 1 17 12 21 18 
   20 12 23 22 
 LP43 1 18 18 21 20 
   23 19 23 21 
 LP44 1 18 12 21 19 
   20 22 26 19 
 LP45 1 17 17 18 16 
   18 18 21 18 
 LP46 1 17 12 23 22 
   19 19 23 23 
 LP47 1 15 20 23 12 
   15 22 26 16 
 LP48 1 19 17 23 18 
   21 19 28 20 
 LP49 1 17 18 18 19 
   21 22 25 21 
 LP50 1 17 12 18 17 
   17 20 19 20 
 LP51 1 17 17 23 19 
   20 20 26 23 
 LP52 1 20 18 24 19 
   21 21 26 19 
 LP53 1 17 20 18 21 
   24 17 22 21 
} 
 
5.6.2 Random White population genotypic LD estimation and haplotype 
estimation project file 
 [Profile]  
 
Title="Random White Population Haplotype Estimation"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 1 
     LocusSeparator= WHITESPACE 
     GameticPhase= 0 
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     RecessiveData= 0 
     RecessiveAllele= null 
     MissingData= '?' 
# Some advenced settings the experienced user can unkomment 
#     Frequency= ABS             # - {ABS, REL}  
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
 
[Data]  
 
[[Samples]]  
 
 SampleName="Random White Population"  
 SampleSize= 30 
 SampleData= {   
 #Sample of genotypic data (4 loci): 
      RW251 1 18 12 18 18 
   18 12 19 20 
      RW252 1 17 12 18 19 
   22 20 23 19 
      RW253 1 16 12 18 20 
   17 19 21 22 
      RW254 1 17 19 19 18 
   20 20 23 20 
      RW255 1 17 12 21 20 
   22 17 23 22 
      RW256 1 18 19 18 16 
   23 24 23 16 
      RW257 1 17 12 18 19 
   22 21 19 20 
      RW258 1 17 19 23 18 
   22 19 23 20 
      RW259 1 18 20 18 20 
   18 21 19 22 
      RW260 1 23 20 2  20 
   23 25 26 20 
      RW261 1 16 19 18 18 
   17 20 24 21 
      RW262 1 17 12 19 18 
   17 19 21 22 
      RW263 1 17 12 18 18 
   21 19 19 21 
      RW264 1 17 20 18 19 
   18 22 23 19 
      RW265 1 17 12 18 16 
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   20 19 23 18 
      RW266 1 15 17 18 18 
   17 19 22 20 
      RW267 1 18 18 23 17 
   18 19 23 19 
      RW268 1 17 12 21 16 
   17 19 24 16 
      RW269 1 18 19 18 16 
   22 20 21 18 
      RW270 1 15 19 21 19 
   18 19 23 19 
      RW271 1 20 12 18 19 
   22 19 23 21 
      RW272 1 17 12 21 20 
   22 20 23 22 
      RW273 1 17 12 18 20 
   17 21 19 22 
      RW274 1 15 21 19 16 
   18 23 21 16 
      RW275 1 18 12 18 20 
   18 20 21 22 
      RW276 1 17 19 18 18 
   18 21 21 20 
      RW277 1 18 19 22 16 
   21 19 25 18 
      RW278 1 15 12 19 18 
   17 19 21 20 
      RW279 1 17 17 18 19 
   17 19 23 20 
      RW280 1 17 12 19 20 
   17 19 21 22 
}  
 
5.6.3 Random Coloured population haplotypic LD estimation project file 
[Profile]  
 
Title="Linkage disequilibrium estimation for the random Coloured Namaqualand 
population"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 0 
     LocusSeparator= WHITESPACE 
     GameticPhase= 0 
     RecessiveData= 0 
     RecessiveAllele= null 
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     MissingData= '?' 
     Frequency= REL              
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
 
[Data]  
 
[[Samples]]  
 
 SampleName="Random Namaqualand Estimated Haplotypes"  
 SampleSize= 81 
 SampleData= {   
RC1 0.01042 15 16 21 19  
RC2 0.01042 15 19 19 21  
RC3 0.01042 15 20 23 12  
RC4 0.02083 15 21 19 18  
RC5 0.01042 15 22 26 16  
RC6 0.01042 15 23 24 22  
RC7 0.01042 15 26 19 20  
RC8 0.01042 16 18 23 19  
RC9 0.01042 16 20 24 20  
RC10 0.01042 17 12 19 17  
RC11 0.01042 17 12 23 16  
RC12 0.03125 17 12 23 18  
RC13 0.01042 17 16 19 24  
RC14 0.01042 17 17 18 21  
RC15 0.01042 17 18 18 18  
RC16 0.01042 17 18 18 20 
RC17 0.03125 17 18 19 21  
RC18 0.01042 17 18 24 19  
RC19 0.01042 17 19 19 18  
RC20 0.02083 17 19 20 21  
RC21 0.02083 17 19 23 22  
RC22 0.01042 17 19 25 22  
RC23 0.01042 17 19 26 22  
RC24 0.01042 17 19 32 19  
RC25 0.01042 17 20 18 20  
RC26 0.01042 17 20 26 19  
RC27 0.01042 17 21 19 20  
RC28 0.01042 17 21 21 22  
RC29 0.01042 17 22 21 17  
RC30 0.02083 17 22 23 20  
RC31 0.01042 17 22 25 21  
RC32 0.01042 17 24 27 16  
RC33 0.01042 17 26 26 21  
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RC34 0.01042 18 17 21 16  
RC35 0.01042 18 17 23 13  
RC36 0.01042 18 17 25 22  
RC37 0.01042 18 17 27 18  
RC38 0.01042 18 18 23 18  
RC39 0.01042 18 18 23 21  
RC40 0.01042 18 19 21 20  
RC41 0.01042 18 19 23 21  
RC42 0.01042 18 19 25 20  
RC43 0.02083 18 20 23 19  
RC44 0.01042 18 20 24 20  
RC45 0.01042 18 20 25 19  
RC46 0.01042 18 21 26 22  
RC47 0.01042 18 22 21 19  
RC48 0.01042 18 22 24 13  
RC49 0.01042 18 23 23 20  
RC50 0.01042 19 12 23 23  
RC51 0.01042 19 12 25 22  
RC52 0.01042 19 17 23 16  
RC53 0.01042 19 17 23 18  
RC54 0.02083 19 18 19 19  
RC55 0.01042 19 19 18 18  
RC56 0.01042 19 19 27 21  
RC57 0.01042 19 20 27 21  
RC58 0.03125 20 12 21 22  
RC59 0.01042 20 12 25 24  
RC60 0.01042 20 12 26 19  
RC61 0.01042 20 17 22 21  
RC62 0.01042 20 17 23 23  
RC63 0.01042 20 17 27 17  
RC64 0.01042 20 18 19 15  
RC65 0.01042 20 18 27 19  
RC66 0.01042 20 21 26 19  
RC67 0.01042 20 22 20 18  
RC68 0.01042 20 22 27 16  
RC69 0.03125 21 18 18 19  
RC70 0.01042 21 18 19 19  
RC71 0.01042 21 18 24 19  
RC72 0.01042 21 19 19 20  
RC73 0.01042 21 19 28 20  
RC74 0.01042 21 20 21 16  
RC75 0.01042 21 22 20 20  
RC76 0.01042 21 22 23 19  
RC77 0.01042 21 22 26 22  
RC78 0.01042 22 20 24 20  
RC79 0.02083 23 18 21 20  
 115 
RC80 0.01042 23 19 19 19  
RC81 0.01042 24 20 22 21 
 } 
 
5.6.4 Random White population haplotypic LD estimation project file 
[Profile]  
 
Title="Linkage disequilibrium estimation using random White haplotypes"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 0 
     LocusSeparator= WHITESPACE 
     GameticPhase= 0 
     RecessiveData= 0 
     RecessiveAllele= null 
     MissingData= '?' 
     Frequency= REL              
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
 
[Data]  
 
[[Samples]]  
 
 SampleName="Random White estimated haplotypes"  
 SampleSize= 43 
 SampleData= {   
 RW1 0.01667 15 12 21 18  
 RW2 0.01667 15 17 22 20  
 RW3 0.01667 15 19 21 19  
 RW4 0.01667 15 23 21 16  
 RW5 0.01667 16 19 18 20  
 RW6 0.01667 16 20 24 21  
 RW7 0.01667 17 12 18 22  
 RW8 0.08333 17 12 21 22  
 RW9 0.01667 17 12 24 16  
 RW10 0.01667 17 17 18 19  
 RW11 0.08333 17 19 18 18  
 RW12 0.01667 17 19 19 18  
 RW13 0.03333 17 19 19 20  
 RW14 0.01667 17 19 21 16  
 RW15 0.05000 17 19 23 20  
 RW16 0.03333 17 20 23 19  
 RW17 0.03333 17 21 19 20  
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 RW18 0.03333 18 12 18 20  
 RW19 0.01667 18 12 19 18  
 RW20 0.01667 18 18 23 17  
 RW21 0.01667 18 19 23 16  
 RW22 0.03333 18 19 23 19  
 RW23 0.01667 18 19 25 16  
 RW24 0.01667 18 20 18 16  
 RW25 0.01667 18 20 19 22  
 RW26 0.01667 18 20 21 22  
 RW27 0.01667 18 21 18 20  
 RW28 0.01667 18 21 19 16  
 RW29 0.01667 18 21 21 20  
 RW30 0.01667 18 22 18 19  
 RW31 0.01667 20 12 23 16  
 RW32 0.01667 20 19 23 21  
 RW33 0.01667 20 20 19 18  
 RW34 0.01667 21 12 19 21  
 RW35 0.01667 21 19 22 18  
 RW36 0.05000 22 12 18 19  
 RW37 0.01667 22 17 23 20  
 RW38 0.01667 22 19 21 18  
 RW39 0.01667 22 19 23 18  
 RW40 0.01667 22 20 23 20  
 RW41 0.01667 23 20 2 20  
 RW42 0.01667 23 24 18 16  
 RW43 0.01667 23 25 26 20 
 }  
 
5.6.5 Coloured LP haplotypic LD project file 
[Profile]  
 
Title="Namaqualand LP Linkage disequilibrium estimate"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 1 
     LocusSeparator= WHITESPACE 
     GameticPhase= 1 
     RecessiveData= 0 
     RecessiveAllele= null 
     MissingData= '?' 
# Some advenced settings the experienced user can unkomment 
#     Frequency= ABS             # - {ABS, REL}  
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
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[Data]  
 
[[Samples]]  
 
 SampleName="Namaqualand LP Haplotypes"  
 SampleSize= 48 
 SampleData= {   
LP1 34 19 12 23 22 
LP2 6 19 12 23 23 
LP3 2 19 12 23 20 
LP4 2 19 12 18 22 
LP5 1 19 12 23 18 
LP6 1 19 12 19 22 
LP7 1 19 12 26 23 
LP8 1 14 12 23 22 
}  
 
5.6.6 White LP haplotypic LD project file 
[Profile]  
 
Title="White LP Linkage disequilibrium Estimation"  
     NbSamples= 1        #Number of sample in the Project. 
     DataType= MICROSAT 
     GenotypicData= 1 
     LocusSeparator= WHITESPACE 
     GameticPhase= 1 
     RecessiveData= 0 
     RecessiveAllele= null 
     MissingData= '?' 
# Some advenced settings the experienced user can unkomment 
#     Frequency= ABS             # - {ABS, REL}  
#     CompDistMatrix= 0          # - {0, 1} 
#     FrequencyThreshold= 1.0e-5 # - (Any real number between 1.0e-7 and 1.e-2) 
#     EpsilonValue= 1.0e-7       # - (Any real number between 1.0e-12 and 1.0e-7) 
 
[Data]  
 
[[Samples]]  
 
 SampleName="White LP Population"  
 SampleSize= 4 
 SampleData= {   
LP1 8 19 12 23 22 
LP9 2 17 12 23 18 
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LP10 1 15 12 23 20 
LP11 1 22 12 23 22 
}  
 
 
5.7 Arlequin result files 
5.7.1 Random Coloured population genotypic LD result file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (08/01/1904 at 15:39:39)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples      =  1 
 DataType       =  MICROSAT 
 GenotypicData  =  1 
 GameticPhase   =  0 
 RecessiveData  =  0 
 
Sample: Random Namaqualand Population 
 
Pairwise linkage disequilibrium: (Random Namaqualand Population) 
 
Test of linkage disequilibrium for all pairs of loci: 
----------------------------------------------------- 
 
Permutation test using the EM algorithm 
Number of permutations: 100000 
Number of initial conditions for EM: 10 
 
Pair(0, 1) : Exact P= 0.0255261  +-  0.000479137 (100172 permutations done)      
Chi-square test value=89.5712 (P = 1,  819 d.f.) 
Pair(0, 2) : Exact P= 0.0707982  +-  0.000819767 (100172 permutations done)      
Chi-square test value=91.5793 (P = 1,  783 d.f.) 
Pair(1, 2) : Exact P= 0.118516  +-  0.00103656 (100172 permutations done)      
Chi-square test value=100.527 (P = 1,  890 d.f.) 
Pair(0, 3) : Exact P= 0.918042  +-  0.000833909 (100172 permutations done)      
Chi-square test value=64.5359 (P = 1,  819 d.f.) 
Pair(1, 3) : Exact P= 0.675538  +-  0.00139915 (100172 permutations done)      
Chi-square test value=81.5169 (P = 1,  950 d.f.) 
Pair(2, 3) : Exact P= 0.558679  +-  0.0016182 (100172 permutations done)      
Chi-square test value=91.3574 (P = 1,  1023 d.f.) 
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Histogram of the number of linked loci per locus 
 
--------------------------------------------------------------------- 
Locus:     0    1    2    3 
--------------------------------------------------------------------- 
                1    1    0    0 
--------------------------------------------------------------------- 
 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   +   -   -  
       1 |  +   *   -   -  
       2 |  -   -   *   -  
       3 |  -   -   -   *  
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (08/01/1904 at 20:49:26)) 
Total ellapsed time for this run : 5h 9m 47s 257 ms 
//////////////////////////////////////////////////////////////////// 
 
5.7.2 Random Coloured population haplotype estimation result file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (08/01/1904 at 12:00:04)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples = 1 
 DataType = MICROSAT 
 GenotypicData = 1 
 GameticPhase = 0 
 RecessiveData = 0 
 
Sample: Random Namaqualand Population 
 
Haplotype frequencies estimation: (Random Namaqualand Population) 
 
No. of gene copies in sample: 96 
No. of random initial conditions for EM: 50 
No. of different maximum likelihoods found: 5 
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Epsilon value for stopping iterations: 1.000000e-07 
Logarithm of the sample maximum-likelihood: -382.018951 
Standard deviations not computed  
 
Maximum-likelihood haplotype frequencies: 
 
Total number of possible haplotypes: 495 
Minimum frequency to reach for output: 1.000e-05 
 
    #   Haplotype     Freq.      s.d. 
    1     UNKNOWN   0.01042     0.00000  15 16 21 19  
    2     UNKNOWN   0.01042     0.00000  15 19 19 21  
    3     UNKNOWN   0.01042     0.00000  15 20 23 12  
    4     UNKNOWN   0.02083     0.00000  15 21 19 18  
    5     UNKNOWN   0.01042     0.00000  15 22 26 16  
    6     UNKNOWN   0.01042     0.00000  15 23 24 22  
    7     UNKNOWN   0.01042     0.00000  15 26 19 20  
    8     UNKNOWN   0.01042     0.00000  16 18 23 19  
    9     UNKNOWN   0.01042     0.00000  16 20 24 20  
   10    UNKNOWN   0.01042     0.00000  17 12 19 17  
   11    UNKNOWN   0.01042     0.00000  17 12 23 16  
   12    UNKNOWN   0.03125     0.00000  17 12 23 18  
   13    UNKNOWN   0.01042     0.00000  17 16 19 24  
   14    UNKNOWN   0.01042     0.00000  17 17 18 21  
   15    UNKNOWN   0.01042     0.00000  17 18 18 18  
   16    UNKNOWN   0.01042     0.00000  17 18 18 20  
   17    UNKNOWN   0.03125     0.00000  17 18 19 21  
   18    UNKNOWN   0.01042     0.00000  17 18 24 19  
   19    UNKNOWN   0.01042     0.00000  17 19 19 18  
   20    UNKNOWN   0.02083     0.00000  17 19 20 21  
   21    UNKNOWN   0.02083     0.00000  17 19 23 22  
   22    UNKNOWN   0.01042     0.00000  17 19 25 22  
   23    UNKNOWN   0.01042     0.00000  17 19 26 22  
   24    UNKNOWN   0.01042     0.00000  17 19 32 19  
   25    UNKNOWN   0.01042     0.00000  17 20 18 20  
   26    UNKNOWN   0.01042     0.00000  17 20 26 19  
   27    UNKNOWN   0.01042     0.00000  17 21 19 20  
   28    UNKNOWN   0.01042     0.00000  17 21 21 22  
   29    UNKNOWN   0.01042     0.00000  17 22 21 17  
   30    UNKNOWN   0.02083     0.00000  17 22 23 20  
   31    UNKNOWN   0.01042     0.00000  17 22 25 21  
   32    UNKNOWN   0.01042     0.00000  17 24 27 16  
   33    UNKNOWN   0.01042     0.00000  17 26 26 21  
   34    UNKNOWN   0.01042     0.00000  18 17 21 16  
   35    UNKNOWN   0.01042     0.00000  18 17 23 13  
   36    UNKNOWN   0.01042     0.00000  18 17 25 22  
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   37    UNKNOWN   0.01042     0.00000  18 17 27 18  
   38    UNKNOWN   0.01042     0.00000  18 18 23 18  
   39    UNKNOWN   0.01042     0.00000  18 18 23 21  
   40    UNKNOWN   0.01042     0.00000  18 19 21 20  
   41    UNKNOWN   0.01042     0.00000  18 19 23 21  
   42    UNKNOWN   0.01042     0.00000  18 19 25 20  
   43    UNKNOWN   0.02083     0.00000  18 20 23 19  
   44    UNKNOWN   0.01042     0.00000  18 20 24 20  
   45    UNKNOWN   0.01042     0.00000  18 20 25 19  
   46    UNKNOWN   0.01042     0.00000  18 21 26 22  
   47    UNKNOWN   0.01042     0.00000  18 22 21 19  
   48    UNKNOWN   0.01042     0.00000  18 22 24 13  
   49    UNKNOWN   0.01042     0.00000  18 23 23 20  
   50    UNKNOWN   0.01042     0.00000  19 12 23 23  
   51    UNKNOWN   0.01042     0.00000  19 12 25 22  
   52    UNKNOWN   0.01042     0.00000  19 17 23 16  
   53    UNKNOWN   0.01042     0.00000  19 17 23 18  
   54    UNKNOWN   0.02083     0.00000  19 18 19 19  
   55    UNKNOWN   0.01042     0.00000  19 19 18 18  
   56    UNKNOWN   0.01042     0.00000  19 19 27 21  
   57    UNKNOWN   0.01042     0.00000  19 20 27 21  
   58    UNKNOWN   0.03125     0.00000  20 12 21 22  
   59    UNKNOWN   0.01042     0.00000  20 12 25 24  
   60    UNKNOWN   0.01042     0.00000  20 12 26 19  
   61    UNKNOWN   0.01042     0.00000  20 17 22 21  
   62    UNKNOWN   0.01042     0.00000  20 17 23 23  
   63    UNKNOWN   0.01042     0.00000  20 17 27 17  
   64    UNKNOWN   0.01042     0.00000  20 18 19 15  
   65    UNKNOWN   0.01042     0.00000  20 18 27 19  
   66    UNKNOWN   0.01042     0.00000  20 21 26 19  
   67    UNKNOWN   0.01042     0.00000  20 22 20 18  
   68    UNKNOWN   0.01042     0.00000  20 22 27 16  
   69    UNKNOWN   0.03125     0.00000  21 18 18 19  
   70    UNKNOWN   0.01042     0.00000  21 18 19 19  
   71    UNKNOWN   0.01042     0.00000  21 18 24 19  
   72    UNKNOWN   0.01042     0.00000  21 19 19 20  
   73    UNKNOWN   0.01042     0.00000  21 19 28 20  
   74    UNKNOWN   0.01042     0.00000  21 20 21 16  
   75    UNKNOWN   0.01042     0.00000  21 22 20 20  
   76    UNKNOWN   0.01042     0.00000  21 22 23 19  
   77    UNKNOWN   0.01042     0.00000  21 22 26 22  
   78    UNKNOWN   0.01042     0.00000  22 20 24 20  
   79    UNKNOWN   0.02083     0.00000  23 18 21 20  
   80    UNKNOWN   0.01042     0.00000  23 19 19 19  
   81    UNKNOWN   0.01042     0.00000  24 20 22 21  
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Sum of all 495 haplotype frequencies: 1.00000 
Sum of 81 listed frequencies: 1.00000 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (08/01/1904 at 12:00:04)) 
Total ellapsed time for this run : 0h 0m 0s 361 ms 
//////////////////////////////////////////////////////////////////// 
 
5.7.3 Random White population genotypic LD result file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (09/01/1904 at 12:54:25)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples      =  1 
 DataType       =  MICROSAT 
 GenotypicData  =  1 
 GameticPhase   =  0 
 RecessiveData  =  0 
 
 
Sample: Random White Population 
Pairwise linkage disequilibrium: (Random White Population) 
Test of linkage disequilibrium for all pairs of loci: 
 
Permutation test using the EM algorithm 
Number of permutations: 100000 
Number of initial conditions for EM: 10 
 
Pair(0, 1) : Exact P= 0.534011  +-  0.00153022 (100172 permutations done)      
Chi-square test value=43.9476 (P = 1,  371 d.f.) 
Pair(0, 2) : Exact P= 0.159086  +-  0.000991606 (100172 permutations done)      
Chi-square test value=47.3711 (P = 1,  371 d.f.) 
Pair(1, 2) : Exact P= 0.0911332  +-  0.000865628 (100172 permutations done)      
Chi-square test value=52.4577 (P = 1,  459 d.f.) 
Pair(0, 3) : Exact P= 0.739618  +-  0.00130345 (100172 permutations done)      
Chi-square test value=35.2883 (P = 1,  357 d.f.) 
Pair(1, 3) : Exact P= 0.15686  +-  0.00101697 (100172 permutations done)      
Chi-square test value=48.032 (P = 1,  495 d.f.) 
Pair(2, 3) : Exact P= 0.285958  +-  0.00140217 (100172 permutations done)      
Chi-square test value=43.6017 (P = 1,  408 d.f.) 
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Histogram of the number of linked loci per locus 
 
--------------------------------------------------------------------- 
Locus:     0    1    2    3 
--------------------------------------------------------------------- 
                0    0    0    0 
--------------------------------------------------------------------- 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   -   -   -  
       1 |  -   *   -   -  
       2 |  -   -   *   -  
       3 |  -   -   -   *  
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (09/01/1904 at 15:21:41)) 
Total ellapsed time for this run : 2h 27m 16s 35 ms 
//////////////////////////////////////////////////////////////////// 
 
5.7.4 Random White population haplotype estimation result file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (08/01/1904 at 11:57:59)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples = 1 
 DataType = MICROSAT 
 GenotypicData = 1 
 GameticPhase = 0 
 RecessiveData = 0 
 
Sample: Random White Population 
Haplotype frequencies estimation: (Random White Population) 
 
No. of gene copies in sample: 60 
No. of random initial conditions for EM: 50 
No. of different maximum likelihoods found: 2 
Epsilon value for stopping iterations: 1.000000e-07 
Logarithm of the sample maximum-likelihood: -204.682220 
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Standard deviations not computed  
 
------------------------------------------ 
Maximum-likelihood haplotype frequencies: 
------------------------------------------ 
 
Total number of possible haplotypes: 248 
Minimum frequency to reach for output: 1.000e-05 
 
    #    Haplotype        Freq.           s.d. 
    1     UNKNOWN   0.01667     0.00000  15 12 21 18  
    2     UNKNOWN   0.01667     0.00000  15 17 22 20  
    3     UNKNOWN   0.01667     0.00000  15 19 21 19  
    4     UNKNOWN   0.01667     0.00000  15 23 21 16  
    5     UNKNOWN   0.01667     0.00000  16 19 18 20  
    6     UNKNOWN   0.01667     0.00000  16 20 24 21  
    7     UNKNOWN   0.01667     0.00000  17 12 18 22  
    8     UNKNOWN   0.08333     0.00000  17 12 21 22  
    9     UNKNOWN   0.01667     0.00000  17 12 24 16  
   10    UNKNOWN   0.01667     0.00000  17 17 18 19  
   11    UNKNOWN   0.08333     0.00000  17 19 18 18  
   12    UNKNOWN   0.01667     0.00000  17 19 19 18  
   13    UNKNOWN   0.03333     0.00000  17 19 19 20  
   14    UNKNOWN   0.01667     0.00000  17 19 21 16  
   15    UNKNOWN   0.05000     0.00000  17 19 23 20  
   16    UNKNOWN   0.03333     0.00000  17 20 23 19  
   17    UNKNOWN   0.03333     0.00000  17 21 19 20  
   18    UNKNOWN   0.03333     0.00000  18 12 18 20  
   19    UNKNOWN   0.01667     0.00000  18 12 19 18  
   20    UNKNOWN   0.01667     0.00000  18 18 23 17  
   21    UNKNOWN   0.01667     0.00000  18 19 23 16  
   22    UNKNOWN   0.03333     0.00000  18 19 23 19  
   23    UNKNOWN   0.01667     0.00000  18 19 25 16  
   24    UNKNOWN   0.01667     0.00000  18 20 18 16  
   25    UNKNOWN   0.01667     0.00000  18 20 19 22  
   26    UNKNOWN   0.01667     0.00000  18 20 21 22  
   27    UNKNOWN   0.01667     0.00000  18 21 18 20  
   28    UNKNOWN   0.01667     0.00000  18 21 19 16  
   29    UNKNOWN   0.01667     0.00000  18 21 21 20  
   30    UNKNOWN   0.01667     0.00000  18 22 18 19  
   31    UNKNOWN   0.01667     0.00000  20 12 23 16  
   32    UNKNOWN   0.01667     0.00000  20 19 23 21  
   33    UNKNOWN   0.01667     0.00000  20 20 19 18  
   34    UNKNOWN   0.01667     0.00000  21 12 19 21  
   35    UNKNOWN   0.01667     0.00000  21 19 22 18  
   36    UNKNOWN   0.05000     0.00000  22 12 18 19  
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   37    UNKNOWN   0.01667     0.00000  22 17 23 20  
   38    UNKNOWN   0.01667     0.00000  22 19 21 18  
   39    UNKNOWN   0.01667     0.00000  22 19 23 18  
   40    UNKNOWN   0.01667     0.00000  22 20 23 20  
   41    UNKNOWN   0.01667     0.00000  23 20 2 20  
   42    UNKNOWN   0.01667     0.00000  23 24 18 16  
   43    UNKNOWN   0.01667     0.00000  23 25 26 20  
 
Sum of all 248 haplotype frequencies: 1.00000 
Sum of 43 listed frequencies: 1.00000 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (08/01/1904 at 11:57:59)) 
Total ellapsed time for this run : 0h 0m 0s 270 ms 
//////////////////////////////////////////////////////////////////// 
 
5.7.5 Truncated random Coloured haplotypic LD estimation result file 
 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (09/01/1904 at 12:38:42)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples = 1 
 DataType = MICROSAT 
 GenotypicData = 0 
 
Sample: Random Namaqualand Estimated Haplotypes 
Pairwise linkage disequilibrium: (Random Namaqualand Estimated Haplotypes) 
 
Test of linkage disequilibrium for all pairs of loci: 
----------------------------------------------------- 
 
 
Exact test using a Markov chain: 
Chain length: 100000 
Dememorization: 1000 
Note: The test is only performed for polymorphic pairs of loci 
 
Pair (0, 1) Exact P=0.105419  +-  0.00093619 (100172 Steps done) 
Pair (0, 2) Exact P=0.0943877  +-  0.000474807 (100172 Steps done) 
Pair (1, 2) Exact P=0.0638602  +-  0.000483281 (100172 Steps done) 
Pair (0, 3) Exact P=0.646069  +-  0.00080982 (100172 Steps done) 
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Pair (1, 3) Exact P=0.00175698  +-  9.79536e-05 (100172 Steps done) 
Pair (2, 3) Exact P=0.272012  +-  0.00125002 (100172 Steps done) 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   -   -   -  
       1 |  -   *   -   +  
       2 |  -   -   *   -  
       3 |  -   +   -   *  
 
Number of linked loci per polymorphic locus (significance level=0.05): 
----------------------------------------------- 
y\Locus:     0    1    2    3   No. of Loci 
------------------------------------------------- 
          1       0    1    0    1            4 
------------------------------------------------- 
          2       0    1    0    1            4 
------------------------------------------------- 
          3       0    1    0    1            4 
------------------------------------------------- 
          4       0    1    0    1            4 
------------------------------------------------- 
          5       0    1    0    1            4 
------------------------------------------------- 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (09/01/1904 at 12:38:43)) 
Total ellapsed time for this run : 0h 0m 0s 580 ms 
//////////////////////////////////////////////////////////////////// 
5.7.6 Truncated random White population haplotypic LD estimation result file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (09/01/1904 at 12:46:07)) 
//////////////////////////////////////////////////////////////////// 
 
 
Project information: 
-------------------- 
 NbSamples  = 1 
 DataType = MICROSAT 
 GenotypicData = 0 
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Sample: Random White estimated haplotypes 
Pairwise linkage disequilibrium: (Random White estimated haplotypes) 
 
Test of linkage disequilibrium for all pairs of loci: 
----------------------------------------------------- 
 
 
Exact test using a Markov chain: 
Chain length: 100000 
Dememorization: 1000 
Note: The test is only performed for polymorphic pairs of loci 
 
Pair (0, 1) Exact P=0.405622  +-  0.00133903 (100172 Steps done) 
Pair (0, 2) Exact P=0.0662061  +-  0.000692723 (100172 Steps done) 
Pair (1, 2) Exact P=0.541089  +-  0.00103682 (100172 Steps done) 
Pair (0, 3) Exact P=0.498972  +-  0.0015881 (100172 Steps done) 
Pair (1, 3) Exact P=0.0693308  +-  0.000531422 (100172 Steps done) 
Pair (2, 3) Exact P=0.41256  +-  0.00168096 (100172 Steps done) 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   -   -   -  
       1 |  -   *   -   -  
       2 |  -   -   *   -  
       3 |  -   -   -   *  
 
Number of linked loci per polymorphic locus (significance level=0.05): 
----------------------------------------------- 
y\Locus:     0    1    2    3   No. of Loci 
------------------------------------------------- 
          1       0    0    0    0            4 
------------------------------------------------- 
          2       0    0    0    0            4 
------------------------------------------------- 
          3       0    0    0    0            4 
------------------------------------------------- 
          4       0    0    0    0            4 
------------------------------------------------- 
          5       0    0    0    0            4 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (09/01/1904 at 12:46:07)) 
Total ellapsed time for this run : 0h 0m 0s 561 ms 
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//////////////////////////////////////////////////////////////////// 
 
5.7.7 Truncated Coloured LP population haplotypic LD estimation results file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (08/01/1904 at 12:50:25)) 
//////////////////////////////////////////////////////////////////// 
 
Project information: 
-------------------- 
 NbSamples = 1 
 DataType = MICROSAT 
 GenotypicData = 1 
 GameticPhase = 1 
 RecessiveData = 0 
 
 
Sample: Namaqualand LP Haplotypes 
Pairwise linkage disequilibrium: (Namaqualand LP Haplotypes) 
 
Test of linkage disequilibrium for all pairs of loci: 
----------------------------------------------------- 
 
 
Exact test using a Markov chain: 
Chain length: 100000 
Dememorization: 1000 
Note: The test is only performed for polymorphic pairs of loci 
 
Pair (0, 1) Exact P=0  +-  0 (100172 Steps done) 
Pair (0, 2) Exact P=0  +-  0 (100172 Steps done) 
Pair (1, 2) Exact P=0  +-  0 (100172 Steps done) 
Pair (0, 3) Exact P=0  +-  0 (100172 Steps done) 
Pair (1, 3) Exact P=0  +-  0 (100172 Steps done) 
Pair (2, 3) Exact P=0  +-  0 (100172 Steps done) 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   +   +   +  
       1 |  +   *   +   +  
       2 |  +   +   *   +  
       3 |  +   +   +   *  
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Number of linked loci per polymorphic locus (significance level=0.05): 
----------------------------------------------- 
y\Locus:     0    1    2    3   No. of Loci 
------------------------------------------------- 
          1       3    3    3    3            4 
------------------------------------------------- 
          2       3    3    3    3            4 
------------------------------------------------- 
          3       3    3    3    3            4 
------------------------------------------------- 
          4       3    3    3    3            4 
------------------------------------------------- 
          5       3    3    3    3            4 
------------------------------------------------- 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (08/01/1904 at 12:50:26)) 
Total ellapsed time for this run : 0h 0m 0s 591 ms 
//////////////////////////////////////////////////////////////////// 
 
5.7.8 Truncated White LP population haplotypic LD estimation results file 
//////////////////////////////////////////////////////////////////// 
RUN NUMBER 1 (08/01/1904 at 12:54:42)) 
//////////////////////////////////////////////////////////////////// 
 
Project information: 
-------------------- 
 NbSamples = 1 
 DataType = MICROSAT 
 GenotypicData = 1 
 GameticPhase = 1 
 RecessiveData = 0 
 
Sample: White LP Population 
Pairwise linkage disequilibrium: (White LP Population) 
 
Test of linkage disequilibrium for all pairs of loci: 
----------------------------------------------------- 
 
 
Exact test using a Markov chain: 
Chain length: 100000 
Dememorization: 1000 
Note: The test is only performed for polymorphic pairs of loci 
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Pair (0, 1) Exact P=0  +-  0 (100172 Steps done) 
Pair (0, 2) Exact P=0  +-  0 (100172 Steps done) 
Pair (1, 2) Exact P=0  +-  0 (100172 Steps done) 
Pair (0, 3) Exact P=0  +-  0 (100172 Steps done) 
Pair (1, 3) Exact P=0  +-  0 (100172 Steps done) 
Pair (2, 3) Exact P=0  +-  0 (100172 Steps done) 
 
Table of significant linkage disequilibrium (significance level=0.05): 
 
          ---------------- 
Locus  # |  0|  1|  2|  3| 
          ---------------- 
       0 |  *   +   +   +  
       1 |  +   *   +   +  
       2 |  +   +   *   +  
       3 |  +   +   +   *  
 
Number of linked loci per polymorphic locus (significance level=0.05): 
----------------------------------------------- 
y\Locus:     0    1    2    3   No. of Loci 
------------------------------------------------- 
          1       3    3    3    3            4 
------------------------------------------------- 
          2       3    3    3    3            4 
------------------------------------------------- 
          3       3    3    3    3            4 
------------------------------------------------- 
          4       3    3    3    3            4 
------------------------------------------------- 
           5       3    3    3    3           4 
------------------------------------------------- 
 
//////////////////////////////////////////////////////////////////// 
END OF RUN NUMBER 1 (08/01/1904 at 12:54:43)) 
Total ellapsed time for this run : 0h 0m 0s 621 ms 
//////////////////////////////////////////////////////////////////// 
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5.8 dHPLC Results 
Table 5-2: Random Black South African dHPLC results 
Exon 
1 
Exon 
2 
Exon 
3 
Exon 
4 
Exon 
5 
Exon 
6pI 
Exon 
6pII 
Exon 
7pI 
Exon 
7pII 
Exon 
8pI 
Exon 
8pII 
Exon 
9 
Exon 
10 
Y N N N Y N N N Y N N N N 
Y N N N N Y N N Y N Y Y N 
N N N Y Y Y N N Y N N N N 
N N N N N Y N Y Y N N N N 
N Y N N N N N Y Y N Y N N 
Y N N N N N Y N N N N Y N 
N N N N N Y N N Y N Y N N 
Y N N N N N N N Y N Y N N 
Y N N N N N N N N N N N N 
N N N N N N N Y N N N Y N 
N N N Y N N N Y Y N N N N 
N N N N N Y N N Y N N N N 
N N N N N N N N N N N N N 
N N N N N N N Y Y N Y Y N 
Y N N N N N N N Y N N N N 
N N N N N Y Y Y Y N N N N 
Y N N N N N Y N N N Y N N 
N N N N Y Y Y Y N N Y N N 
N N N N Y N Y N N N Y N N 
Y N N N N N Y N N N Y N N 
Y indicates that a dHPLC shift was seen in a sample, while N indicates that there was no dHPLC shift seen. 
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Table 5-3: Random Coloured Namaqualand dHPLC results 
Exon 
1 
Exon 
2 
Exon 
3 
Exon 
4 
Exon 
5 
Exon 
6pI 
Exon 
6pII 
Exon 
7pI 
Exon 
7pII 
Exon 
8pI 
Exon 
8pII 
Exon 
9 
Exon 
10 
N Y N N Y N N N Y Y N N N 
N N N N N Y N Y Y N N N N 
N N N N N Y N Y Y N N N N 
N N N N N N Y N Y N N N N 
N Y N N Y N N Y N N Y Y N 
N N N N N Y N Y Y N N N N 
Y N N N N N N N N N N N N 
Y N N N N N N N N N N N N 
N N N N N Y N Y Y N Y N N 
N N Y N N N N N N N N N N 
N N N N N Y N Y Y Y N N N 
N N N N N Y N Y Y Y Y N N 
N Y N N N Y N Y N N N N N 
N N N N N N N N N N N N N 
N Y N N N N N N N N N N N 
N N N N N Y Y Y Y N N N N 
N N N N N N N N N N N N N 
N N N N N N N N N N N N N 
N N N N N Y N N Y N Y N N 
Y N N N N Y N N N N N N N 
Y indicates that a dHPLC shift was seen in a sample, while N indicates that there was no dHPLC shift seen. 
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Table 5-4: Random White South African dHPLC results 
Exon 
1 
Exon 
2 
Exon 
3 
Exon 
4 
Exon 
5 
Exon 
6pI 
Exon 
6pII 
Exon 
7pI 
Exon 
7pII 
Exon 
8pI 
Exon 
8pII 
Exon 
9 
Exon 
10 
N N N N Y Y N N N Y N N N 
N N Y Y N Y N N Y N Y N N 
N N Y N N Y N Y Y N Y N N 
N N Y N N Y N Y Y N Y Y N 
Y N N N N Y N Y Y N N N N 
Y N N N N N N Y Y N N N N 
N N Y N N N N Y Y N N N N 
N N Y N N N N N N N N N N 
N N N N N N N N N N N Y N 
N N Y N N Y N N N N N N N 
N N Y N N Y N N N N N N N 
Y N Y N N N N Y Y N N N N 
N N Y N N N N Y Y N N N N 
N N Y N Y N N N Y N N N N 
N N Y N N Y N N N N N N N 
Y N N N N Y N N N N N N N 
N N N N N Y N Y Y N N N N 
N N N Y N N N N Y N N N N 
N N N N N Y N Y Y N N N N 
N N N N N Y N Y N N N N N 
Y indicates that a dHPLC shift was seen in a sample, while N indicates that there was no dHPLC shift seen. 
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5.9 Reagents used during this study 
 
0.025µm Filter Paper 
Available from Millipore 
 
0.5M EDTA (pH 8) 
93.06g EDTA (available from Merck) 
500ml  ddH2O 
 
pH to 8 with 5M NaOH. 
 
1Kb Ladder 
250µl 1 Kb ladder (available from Invitrogen) 
125µl Ficoll Dye 
2.1ml TE buffer 
 
1Kb plus Ladder 
250µl 1 Kb plus ladder (available from Invitrogen) 
125µl Ficoll Dye (available from Sigma) 
2.1ml TE buffer 
 
1% Alcanox 
1g Alcanox (available from Aldrich Chemical company, Inc) 
100ml ddH2O 
 
1x TBE Buffer 
1ml 10x TBE buffer 
9ml ddH2O 
 
1x TE Buffer pH 8.0 
5ml 10mM Tris (available from Merck) 
1ml 1mM EDTA 
 
Make up to 500ml with ddH2O. pH with HCl if necessary. Autoclave. 
 
10% BSA 
1µl 100% BSA (available from Promega)  
 
3% Agarose Gel 
300ml 1x TBE 
9g  Agarose (available from Hispangar) 
 
Mix agarose and 1x TBE. 
Heat until all agarose is dissolved. 
Allow to cool, but mixture must still be liquid. 
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Add 9µl ethidium bromide and mix. 
Pour into gel tray and allow to set. 
 
4.3% Acrylamide Solution 
10.6ml Acrylamide/Bis acrylamide (available from Promega) 
10ml 10x TBE 
36g Urea (available from Promega) 
50ml ddH2O 
 
4.3% Polyacrylamide Gel 
40ml 4.3% acrylamide solution 
200µl APS (available from Analar) 
24µl Temed (available from Promega) 
 
10%SDS 
10g SDS (available from BDH Laboratory Supplies) 
100ml ddH2O 
 
Weigh SDS in a fume hood. 
 
10x TBE Buffer 
108g  Tris base 
55g Boric acid (available from Sigma) 
7.4g EDTA 
 
Make up to 1l with ddH2O. Autoclave. 
 
70% Ethanol 
70ml Ethanol (available from BDH Laboratory Supplies) 
30ml ddH2O 
 
Acetonitrile 
Available from Riedel-de Haen 
 
Big Dye v3.1 
Available from Applied Biosystems. 
 
Big Dye v3.1 Buffer 
Available from Applied Biosystems. 
 
BfaI 
Available from New England Biosystems. 
 
ddH2O 
H2O is distilled and then passed through a Millipore filtration system. Autoclave if using 
in a PCR reaction. 
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Dextran-Formamide Dye 
10ml Formamide (available from Fluka) 
10mg Bromophenol Blue (available from Merck) 
200µl 0.5M EDTA pH 8.0 
 
dNTP Mix (125mM) 
125µl 10mM dATP (available from Invitrogen) 
125µl 10mM dCTP (available from Invitrogen) 
125µl 10mM dGTP (available from Invitrogen) 
125µl 10mM dTTP (available from Invitrogen) 
 
Make up to 1ml with ddH2O. 
 
Ethidium Bromide 
Available from Sigma. 
 
Ficoll Dye 
5g  sucrose (available from Gibco BRL) 
1ml  0.5M EDTA (pH 7.0) 
0.01g  bromophenol blue 
1g  ficoll (available from Sigma) 
 
Make up to 10ml with ddH2O. 
 
NEBuffer 4 
Available from New England Biosystems 
 
Nucleospin Extract columns 
Available from Mackerey-Nagel 
 
PCR Buffer 
Available from Roche 
 
Primers 
Available from Inqaba Biotec 
 
Proteinase K Solution 
100mg Proteinase K 
10ml ddH2O  
 
Rox Size Standard 
Available from Applied Biosystems 
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Saturated NaCl 
Add NaCl to ddH2O until the NaCl no longer dissolves. (available from South African 
Point Instruments) 
 
Sigma Spin Post Reaction Purification columns 
Available from Sigma 
 
Sucrose-Triton X Lysing Buffer 
10ml 1M Tris-HCl pH 8.0 (available from Merck) 
5ml 1M MgCl2 (available from Merck) 
10ml Triton X  (available from BDH Laboratory Supplies) 
109.5g Sucrose (available from Gibco) 
 
Make up to 1l with ddH2O. Autoclave. 
 
T20E5 
20mM Tris pH 8.0 
5mM EDTA 
 
Make up to volume with ddH2O. Autoclave. 
 
Taq 
Available from Roche. 
 138 
5.10 Ethics clearance certificates 
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